

Curriculum Vitae

W. David Hardy, M.D.

PERSONAL HISTORY:

Office Address: 6123 Maryland Drive
Los Angeles, California 90048
Office Phone: (310) 709-3505
Email: wdavidhardymd@gmail.com
Mobile Phone: (310) 709-3505
Place of Birth: Dallas, Texas
Citizenship: United States of America
Partner: Barry Goldblatt

EDUCATION & TRAINING:

1974-1977 University of Texas at Austin, Texas; (Zoology/Classics) *Summa Cum Laude*
1977-1981 Baylor College of Medicine, Houston, Texas; Doctor of Medicine with Honors
1981-1982 Internship in Internal Medicine, Department of Medicine, Baylor College of Medicine Affiliated Hospitals, Houston, Texas
1982-1984 Residency in Internal Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California
1984-1986 Clinical Fellowship in Infectious Diseases and Clinical Immunology (Mentors-Michael S. Gottlieb, MD/Lowell Young, MD), Department of Medicine, University of California - Los Angeles School of Medicine, Los Angeles, CA
1984-1986 Clinical Research Fellowship (Mentor-Michael S. Gottlieb, MD), UCLA AIDS Center, Department of Medicine, University of California – Los Angeles School of Medicine, Los Angeles, California
1998-2002 Laboratory Research Fellowship, Laboratory of Irvin S. Y. Chen, Ph.D., Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA

LICENSURE:

State of Texas: #F-9536, (inactive)
State of California: #C-40623, (active)
District of Columbia: #MD043801, (active)

BOARD CERTIFICATION:

1984 Diplomat, Internal Medicine, American Board of Internal Medicine
2015 Diplomat, Infectious Diseases, American Board of Internal Medicine

PROFESSIONAL EXPERIENCE:

- 1984-1986 Staff Physician, Department of Medicine, UCLA School of Medicine, Los Angeles, California
- 1986 Visiting Assistant Professor, Division of Clinical Immunology/Allergy, Department of Medicine, University of California-Los Angeles School of Medicine, Los Angeles, California
- 1986-1987 Assistant Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, University of California-San Diego School of Medicine, San Diego, California (Full-time Faculty)
- 1986-1987 Co-Investigator, NIH/NIAID-sponsored AIDS Clinical Trials Unit (ACTU), University of California-San Diego School of Medicine, San Diego, California
- 1986-1987 Staff Physician, Owen Clinic (HIV Outpatient Clinical Services), University of California-San Diego School of Medicine, San Diego, California
- 1987-1993 Assistant Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, University of California-Los Angeles School of Medicine, Los Angeles, California (Full-time Faculty)
- 1987-1996 Director, Infectious Diseases/Immunology (HIV/AIDS) Clinic, Department of Medicine, UCLA Medical Center, Los Angeles, California
- 1987-1996 Co-Investigator, NIH/NIAID-sponsored AIDS Clinical Trials Unit (ACTU), University of California-Los Angeles School of Medicine, Los Angeles, California
- 1988-2010 President and Cofounder, Los Angeles Physicians AIDS Forum (LAPAF), UCLA Center for AIDS Research and Education (CARE; 1988-1996), Independent HIV/AIDS-focused Continuing Medical Education (CME) Provider, Los Angeles, California
- 1990-1996 Co-Principal Investigator, NIH/NEI-sponsored Studies of the Ocular Complications of AIDS (SOCA), Department of Ophthalmology, University of California-Los Angeles School of Medicine, Los Angeles, California
- 1993-1996 Associate Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, California (Accelerated Promotion on Full-time Faculty)
- 1993-1996 Principal Investigator, NIH/NIAID-sponsored, Multidisciplinary HIV/AIDS Training Grant (T32AI07388), UCLA AIDS Institute, University of California-Los Angeles School of Medicine, Los Angeles, California
- 1994-1996 Associate Director for Community Liaison, UCLA AIDS Institute, University of California-Los Angeles School of Medicine, Los Angeles, California
- 1994-1996 Program Director, Infectious Diseases Fellowship Training Program, Division of Infectious Diseases, Department of Medicine, University of California-Los Angeles School of Medicine, Los Angeles, California

- 1996-2002 Clinical Associate Professor of Medicine, Department of Medicine, University of California-Los Angeles School of Medicine, Los Angeles, California (Volunteer Teaching Faculty)
- 1996-2002 Scientific Director of Research, Research Department, Pacific Oaks Medical Group, Beverly Hills, California
- 1996-2002 Private Practice Specializing in Infectious Diseases and HIV Medicine, Pacific Oaks Medical Group, Beverly Hills, California
- 2002-2009 Principal Investigator, NIH/NIAID - K08 AI-49759-01A2, “*Developing Foamy Virus Vectors for HIV-1 Vaccine Applications*”, Cedars-Sinai Medical Center, Los Angeles, California (5-year grant with 2, 1-year no-cost extensions)
- 2002-2013 Director, Division of Infectious Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
- 2002-2012 Associate Professor of Medicine-in-Residence, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
- 2002-2013 Associate Program Director, Cedars-Sinai-UCLA Multi-campus Infectious Diseases Fellowship Training Program (Cedars-Sinai Medical Center, Olive View-UCLA Medical Center, Greater Los Angeles VA Medical Center), Los Angeles, California
- 2003-2012 Co-Principal Investigator, NIH/ NIAID-funded U01, “*Solid Organ Transplantation in HIV: Multi-site Study*”, Departments of Medicine and Surgery, Cedars-Sinai Medical Center, Los Angeles, California
- 2007-2012 Co-Investigator, NIH/NIMH-funded R01, “*HIV, Aging and Cognition: A Synergism?*”, Department of Psychiatry and Behavioral Medicine, Cedars-Sinai Medical Center, Los Angeles, California
- 2008-2011 Associate Program Director, NIH/NCRR-sponsored General Clinical Research Center (GCRC), Cedars-Sinai Medical Center, Los Angeles, California
- 2011-2013 Associate Program Director, NIH/NCATS-sponsored Clinical and Translational Research Center (CTRC), UCLA CTSI, Cedars-Sinai Medical Center site, Los Angeles, California
- 2012-2015 Clinical Professor of Medicine, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California [Full-time Faculty (2012-2013), Volunteer Faculty (2013-2015)]
- 2013-2014 U.S. Medical Officer, State of California Institute of Regenerative Medicine (CIRM)-funded/private (Calimmune) collaborative phase I studies of gene-modified CD4+ T cells and CD34+ hematopoietic stem/progenitor cells to cure HIV infection
- 2014-2015 Chief Medical Officer, State of California Institute of Regenerative Medicine (CIRM)-funded/private (Calimmune) collaborative phase I studies of gene-modified CD4+ T cells and CD34+ hematopoietic stem/progenitor cells to cure HIV infection

- 2015-2018 Senior Director of Evidence-based Practices, Whitman-Walker Health; Clinical Research Site (CRS) Leader, AIDS Clinical Trials Group (ACTG); Co-Investigator, Multicenter AIDS Cohort Study (MACS), Investigator and Executive Committee, District of Columbia CFAR; Investigator and Steering Committee, Martin Delaney HIV Cure Collaboratory, Washington DC
- 2015-2020 Adjunct Professor of Medicine, Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD
- 2016-2018 Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC
- 2018-present Scientific and Medical Consultant
- 2019-present Member, FDA Antimicrobial Drugs Advisory Committee (AMDAC)

PROFESSIONAL ACTIVITIES:

Quality Improvement Committees:

- 2002-2013 Co-Chairman, Pulmonary-Infectious Diseases Performance Improvement Committee, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
- 2002-2013 Member, Department of Medicine Performance Improvement Committee, Cedars-Sinai Medical Center, Los Angeles, California
- 2002-2013 Member, Antibiotic Utilization Review Committee, Pharmacy Department, Cedars-Sinai Medical Center, Los Angeles, California
- 2008-2013 Member, Hospital-acquired Infection Task Force, Cedars-Sinai Medical Center, Los Angeles, California; Hand Hygiene Working Group; Antibiotic Stewardship

Academic Service Committees

- 2005-2013 Member, Institutional Biosafety Committee (IBC), Burns Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
- 2006-2012 Member, Committee on Academic Appointments and Promotions, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California
- 2007-2013 Member, Scientific Advisory Committee, General Clinical Research Center, Burns Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
- 2007-2013 Member, Physician Well-Being Committee, Medical Staff Office Cedars-Sinai Medical Center, Los Angeles, California
- 2009-2013 Member, Graduate Medical Education Committee, Academic Affairs, Cedars-Sinai Medical Center, Los Angeles, California
- 2010-2013 Member, Institutional Review Board (IRB), Burns Research Institute, Cedars-Sinai Medical Center, Los Angeles, California

Scientific Committees

- 1988-1993 NIH/NIAID-AIDS Clinical Trials Group (ACTG) Opportunistic Infection Committee and Protozoan Pathogen Study Group
- 1990-1996 NIH/NEI-Steering Committee for Studies of the Ocular Complications of AIDS (SOCA)
- 1992-2010 Co-Chairman, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 17th, 19th and 20th National HIV Clinical Care Options (CCO) for HIV CME Conference
- 1993-1996 NIH/NIAID-ACTG Opportunistic Infection Committee – Viral Pathogen Study Group
- 1993-1996 NIH/NIAID-ACTG Primary Infection, Phase II/III Clinical Trials Working Group
- 1992, 1994, 2000, 2002 Scientific Organizing Committee, 1st, 2nd, 5th and 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland
- 2007 American Academy of HIV Medicine (AAHIVM)/American Heart Association (AHA) Joint Committee on Cardiovascular Complications in HIV-infected Patients, AAHIVM, Washington, DC; Prevention strategies for cardiovascular diseases in HIV-infected patients writing subcommittee
- 2010-present Centers for Disease Control and Prevention (CDC) Prevention with Positives (PwP) Review Committee and Consultant, CDC, Atlanta, Georgia
- 2016-2018 Performance Evaluation Committee (PEC), AIDS Clinical Trials Group (ACTG)
- 2016-present Investigator Member-at-Large, Viral Reservoirs and Eradication (Cure) Transformative Science Group (TSG), AIDS Clinical Trials Group (ACTG)
- 2017-present Co-chair, ACTG 5370 (Phase 1/2a Study of Safety and Immunoactivity of Anti-PD-1 Antibody (cemiplimab) in Virologically-suppressed HIV+ Persons)

Community Organizations

- 1990-1996 Medical Advisory Board (Chairman), Los Angeles Gay and Lesbian Community Services Center, Los Angeles, California
- 1990-1996 Board of Directors, AIDS Project - Los Angeles (APLA), Los Angeles, California – Chairman, Public Policy Committee (1991-1992)
- 1990-2000 Scientific Advisory Committee, Search Alliance (Community-based clinical research organization), Los Angeles, California
- 1991-1994 Board of Directors, Southwest Community-based AIDS Trials Group [NIH-sponsored Community Program for Clinical Research on AIDS (CPCRA)], Los Angeles, California

- 1996-2015 Ambassadors Council, AIDS Project – Los Angeles (APLA), Los Angeles, California
- 1996-2007 Medical Advisory Committee, AIDS Healthcare Foundation (AHF; HIV healthcare providing organization), Los Angeles, California
- 2000-2006 Board of Directors, Project Angel Food (home delivery of meals to person with AIDS and other life-threatening illnesses), Los Angeles, California
- 2008-2015 Board of Directors, Aid for AIDS (housing, financial assistance and food for persons and families with AIDS), Los Angeles, California
- 2012-2015 Board of Directors, AIDS Research Alliance (community-based, HIV Cure and clinical research organization), Los Angeles, California
- 2013-2015 Chairman, Board of Directors, AIDS Research Alliance (community- based, HIV Cure and clinical research organization), Los Angeles, California

PROFESSIONAL ASSOCIATIONS

- 1984-present American College of Physicians (ACP), Member
- 1985-present American Society for Microbiology (ASM)
- 1985-present Infectious Diseases Society of America (IDSA)
- 1988-present International AIDS Society (IAS)
- 1988-2010 Los Angeles Physicians AIDS Forum (President and Co-founder)
- 1989-present International Society for Antiviral Research
- 2001-present HIV Medicine Association (HIVMA) – Research Awards Committee (2010-2014); Board of Directors, Infectious Disease Representative (2011-2014), Board of Directors (2016-2020), Vice-chair (2016-2017), Chair-Elect (2017-2018), Chair (2018-2019), Immediate-Past-Chair (2019-2020)
- 2000-present American Academy of HIV Medicine (AAHIVM)
- 2005-2008 Chairman, Board of Directors, California Chapter of the AAHIVM
- 2005-present National Board of Directors, AAHIVM – Chairman, Education Committee (2008-present) – Member, Executive Committee (2008-present)

HONORS AND SPECIAL AWARDS

- 1993 Commitment to Service Award from Los Angeles Shanti Foundation (provider of emotional and psychological support for persons with HIV/AIDS; \$30,000 Research Award)
- 2007 Spirit of Hope Award from Being Alive – Empowering People with HIV/AIDS (Community-based HIV/AIDS Service Organization)
- 2010 Clinical Trial Exceptional Service Award from the Pharmaceutical Researchers and Manufactures Association (PhRMA)

- 2011 Alliance Humanitarian Award from Alliance for Housing & Healing (Aid for AIDS/Serra Project – provides house and direct financial grants to persons and families with HIV)
- 2012 Research Achievement Award; AIDS Research Alliance, World AIDS Day Concert Ceremony, Los Angeles, California

RESEARCH GRANTS

Previous Research Support as Senior Director of Research Department, Whitman-Walker Health (2015-2018)

2014/04/01 – 2019/03/31

U01 AI035042 Margolick (PI) 2.4 calendar

NIH/NIAID \$1,869,107

Subcontract: Hardy (site PI)

Multicenter AIDS Cohort Study: Natural History Study of HIV-1 in Gay and Bisexual Men

The MACS is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men.

2015/12/01 – 2018/11/30

3U01 AI069503-03S2 Greenberg (PI) 0.84 calendar

NIH/NIAID, \$161,565

Subcontract: Hardy (site PI)

Development of a Citywide Cohort of HIV-infected Persons in Care in the District of Columbia: The DC Cohort

This project will establish a city-wide cohort that will describe clinical outcomes, and improve the quality of care for outpatients with HIV/AIDS in Washington, DC.

2017/06/01-2018/31/08

5P30AI117970-03 Greenberg (PI) 0.6 calendar

NIH/NIAID \$12,000

Subcontract Hardy (PI)

DC CFAR Executive Leadership Board

2013/10/12-2020/11/30

UM1 AI069465-10 Flexner (PI) 2.4 calendar

NIH/NIAID \$2,047,780

Subcontract: Hardy (PI)

Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)

The goals of this project are to support AIDS research through support of clinical studies. The studies of the AIDS Clinical Trials Group (ACTG) are supported through this grant.

Role: CRS Leader

2016/07/01-2021/06/30

1UM1AI12661701 Nixon (PI) 1.44 calendar

NIH/NIAID \$291,076

Subcontract: Hardy (site PI)

BELIEVE: Bench-to-Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
BELIEVE is a new Martin Delaney HIV Cure Collaboratory seeking to create and translate new technologies aimed at curing HIV infection.

2017/07/01-2022/06/30

R01DA043089 Celentano (PI)

NIH/NIDA

\$429,521

0.6 calendar

Subcontract: Hardy (site PI)

Identifying and Engaging Urban HIV-infected and -uninfected Young Black and Latino Men Who Have Sex with Men (YBLMSM) in Care.

This 3-city proposal seeks to address disparities of HIV in YBLMSM in a multilevel intervention to identify, link retain and engage, high-risk uninfected and HIV infected urban YBLMSM in prevention and treatment cascade.

2017/12/01-2022/11/30

UG3AI133669 Wirtz/Reisner (co-PIs)

NIH/NIAID/NIMH/NICHD

\$140,000

0.42 calendar

Subcontract: Hardy (site PI)

American Cohort to Study HIV Acquisition among Transgender Women at High Risk (LITE Cohort)

The American Cohort study proposes to establish multi-site, longitudinal cohort of transgender women in the eastern and southern U.S. (Boston, New York City, Baltimore-Washington, Atlanta, and Miami) to characterize risk factors for HIV acquisition, access to biobehavioral HIV prevention methods, and linkage to care for those who HIV seroconvert.

Previous Research Support as Associate Professor/Professor of Medicine, UCLA School of Medicine and Director, Division of Infectious Diseases, Cedars-Sinai Medical Center (2002-2013)

NIH and Foundation Support

NIH NCATS CTSI – UL1RR033176 (PI-Melmed)

Clinical and Translational Research Institute (CTSI) at UCLA

Clinical and Translational Research Institute (CTSI) is funded by the NIH NCRRT to provide an infrastructure to investigators to facilitate their clinical and translational research, in a primarily outpatient and community-based settings and with access to core lab facilities.

Role: Assistant Program Director – .4 calendar

Cost: \$72,000 (in annual salary support)

Duration: 3/01/2011-2/29/16

Cedars-Sinai Medical Center Finance Department and Intellectual Property Department

East Meets West: In-Vitro Study of Herbal Medicines against Resistant Bacteria

This project analyzes the antibacterial activity of herbal extracts in in vitro experiments alone as well as in combination with synthetic antibiotics against multidrug-resistant(MDR) bacteria.

The goal of this research is to identify a specific molecular compound conferring antibacterial properties.

Role: Principal Investigator – 0.12 calendar

Cost: \$391,158

Duration: 10/1/2009-9/30/2013

NIH/NIAID - K08 AI-49759-01A2 (PI-Hardy)

Number: PA-00-003

Developing Foamy Virus Vectors for HIV-1 Vaccine Applications

The goals of the study are to develop and optimize recombinant HIV-1/Foamy virus vectors.

KO8 Mentored Clinical Scientist Development Award.

Role: Principal Investigator; 75% Effort Total

Direct Costs: \$515,000

Duration: 08/01/02 – 04/30/09 (no cost extensions)

NIH/NIAID - 1 U01 AI052748-01A1 (PI-Stock)

Solid Organ Transplantation in HIV; Multi-Site Study

The primary aim of this study is to evaluate the safety and efficacy of solid organ transplantation in people with HIV disease by conducting a prospective, multi-center cohort study of HIV-positive (+) patients who undergo kidney or liver transplantation.

Role: Site Co-PI - .012 calendar

Annual Direct Cost: \$120,000

Duration: 08/15/03 – 01/31/10; 2/1/2010 – 7/31/2013

NIH/NIMH – 5R01MH058532-10 (PI-Goodkin)

HIV, Aging and Cognition: A Synergism?

The goal of this project is to determine if age interacts with HIV infection to result in a higher prevalence and more rapid progression of cognitive-motor impairment, decreases in functional status, decreases in CD4+ cell count, increases in viral load, progression of CDC stage, and decreased survival time.

Role: Co-investigator – 0.12 calendar

Annual Direct Cost: \$436,665

Duration: 01/26/2007 – 11/30/2008; 12/1/2008 – 12/31/2012

NIH/NCRR – M01-RR00425 (PI-Melmed)

General Clinical Research Center

General Clinical Research Center is funded by the NIH NCRR to provide an infrastructure to investigators to facilitate their clinical research, in a primarily outpatient setting and with access to core lab facilities.

Role: Assistant Program Director - .4 calendar

Cost: \$72,000 (in salary support)

Duration: 11/30/2008 – 12/01/2011

UCLA AIDS Institute/Pendelton Trust Seed Grant

Foamy Virus Vectors for Gene Therapy and Vaccine Studies

The purpose of this study is to optimize foamy virus vectors for future use as HIV vaccine and potential gene therapy applications.

Role: Principal Investigator

Cost: \$50,000

Duration: 05/01/2004 – 04/30/2006

International Antiviral Therapy Evaluation Consortium (IATEC)

05-IAT-0110

A Randomized, Controlled, Open-label, 48-week Study to Assess Differences in Changes in Plasma Lipid Profile Between Patients on Saquinavir/Ritonavir or Atazanavir/Ritonavir in Combination with Tenofovir Disoproxil Fumarate and Emtricitabine as a First-line Regimen

The purpose of this study is to compare several outcomes to two different once-daily protease inhibitor PI-based + Truvada® anti-HIV treatment medication regimens.

Role: Principal Investigator - .012 calendar

Cost: \$46,067

Duration: 10/01/2006 – 09/30/2009

Industry-sponsored Research

Gilead Sciences

Protocol # GS-US-236-0102

A Phase3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 vs (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

The primary objective of this study is to evaluate the safety and efficacy of a regimen containing the quadruple agent co-formulated single tablet of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat vs triple agent co-ormulated single tablet of efavirenz/emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adult subjects.

Role: Principal Investigator

Cost: \$167,400

Duration: 2/1/2010 – 12/31/2013

GSK/ViiV Healthcare

GSK-113086/SPRING2

A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily vs Raltegravir 400 mg Twice Daily Both Administered with Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy-naïve Adult Subjects

The goal of this study is to compare a new investigational integrase inhibitor drug dolutegravir (GSK 1349572) dosed at 50 mg once daily vs raltegravir 400mg twice daily, currently the only FDA-approved integrase inhibitor and thus the current standard-of-care, both with either abacavir/lamivudine or tenofovir DF/emtricitabine, in treatment-naïve, HIV-1-infected subjects.

Role: Principal Investigator

Cost: \$57,425

Duration: 11/1/2010 – 10/31/2013

GSK/ViiV Healthcare
GSK-111761/SAILING

A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK 1349572 50 mg Once Daily vs Raltegravir 400 mg Twice Daily, both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults

The goal of this study is to compare the antiviral efficacy of the new investigational integrase inhibitor dolutegravir (GSK 1349572) dosed at 50 mg once daily compared to raltegravir 400 mg twice daily both in combination with a background regimen consisting of one to two fully active agents in HIV-1-infected, integrase inhibitor naïve, therapy-experienced subjects.

Role: Principal Investigator

Cost: \$50,888

Duration: 12/6/2010 – 12/5/2013

Gilead Sciences
GS-US-264-0110

A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine / Rilpivirine / Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-naïve Adults

The primary objective of this study is to evaluate the efficacy of a single tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) compared with a single tablet regimen of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) in HIV-1 infected, antiretroviral treatment-naïve adult subjects.

Role Principal Investigator

Cost: \$118,675

Duration: 3/1/2012 – 3/1/2014

Pfizer/ViiV
A4001095

A Multicenter, Randomized, Double Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine/Tenofovir + Darunavir/Ritonavir for Treatment of Antiretroviral-Naïve HIV-infected Patients With CCR5 Tropic HIV-1

The study aims to examine whether or not a once-daily dosing of the new combination of maraviroc (Selzentry®) with darunavir (Prezista®) and ritonavir (Norvir®) will be as safe and effective as another once-daily combination routinely used containing darunavir, ritonavir, and Truvada® (a combination of emtricitabine and tenofovir). Maraviroc belongs to a relatively new class of drugs called CCR5 inhibitors which block HIV from entering a target cell.

Role: Principal Investigator

Cost: \$96,000

Duration: 12/1/2011 – 11/3/2013

Vertex
VX11-950-115

An Open-Label, Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)

The proposed study (Vx 11-950-115) is a phase III clinical study to confirm the effectiveness of the new protease inhibitor, telaprevir in HCV treatment in HIV co- infected patients. This study will enroll individuals infected with HIV and HCV genotype 1 who have or have not received prior anti-HCV drug treatment.

Role: Principal Investigator

Cost: \$120,000

Duration: 3/1/2012 – 2/28/2014

Gilead

GS-US-334-0123

*A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 (sofosbuvir) plus Ribavirin for 12 Weeks in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (*HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects*

This is a phase III clinical study to investigate the effectiveness and safety of a new HCV drug, GS-7977 plus Ribavirin for 12 weeks or 24 weeks for HCV treatment in HIV-HCV co-infected patients.

Role: Principal Investigator

Cost: \$130,000

Duration: 9/1/2012 – 8/31/2014

Gilead Sciences

GS-US-236-0103

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/cobicistat vs. Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

The primary objective of this study is to evaluate the safety and efficacy of a regimen containing the quadruple agent co-formulated single tablet of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adult subjects.

Role: Principal Investigator

Cost: \$20,125

Duration: 2/1/2010 – 1/31/2013

Bionor Immuno AS (Norwegian biotech company)

CSR202258; Proj ID #217810

Protocol CT-BI Vacc-4x2007/1: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART

The primary purpose of this study is to evaluate the effect of Vacc-4x immunization versus placebo on CD4+ cell counts, T-cell function and T-cell proliferation, response to treatment

interruption of antiretroviral therapy and the proportion of subjects restarting treatment within 24 weeks after stopping ART.

Role: Principal Investigator

Cost: \$108,328

Duration: 05/19/2008 – 04/18/2012

Merck – CSRI #200387

V520-022

A phase II, multi-center, double-blind, randomized, placebo- controlled probe study with an additional open-label control arm to evaluate the safety and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 gag Vaccine in subject with chronic hepatitis C virus infection

Role: Principal Investigator - .06 calendar

Cost: \$15,750

Duration: 05/014/04 – 9/30/2005

Boehringer Ingelheim

1182.12

Phase III, Open-label, Randomized, Parallel Group Pharmacokinetics Trial of Tipranavir (TPV/RTV), Alone or in Combination with Saquinavir (SQV), Amprenavir (APV) or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced Patients

Role: Principal Investigator

Cost: \$51,110

Duration: 6/14/2004 – 1/31/2007

Boehringer Ingelheim

1182.17

Clinical Trial 1182.17 - A Long-term Open-label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir use in HIV-1 Infected Subjects

Role: Principal Investigator

Cost: \$13,814

Duration: 9/01/2004 – 8/31/2008

Pfizer

1029

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy Alone for the Treatment of Antiretroviral- Experienced, non-CCR5-tropic HIV-1 Infected Subjects

The purpose of this study is to determine whether the new study drug, UK-427, 857 has effective anti-HIV activity in treatment-experienced patients with few remaining treatment options, who have either mixed tropic (both CCR5 and CXCR4) and non CCR- 5 tropic HIV.

Role: Principal Investigator - .06 calendar

Cost: \$12,500

Duration: 01/01/2005 – 12/31/06

GlaxoSmithKline
GRZ107460

A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults

This study is to evaluate GSK364735 (an integrase inhibitor) for the treatment of HIV infection. Integrase inhibitors are a new class of anti-HIV medications. For HIV to reproduce, its genetic make-up must be spliced into the genetic make-up of the human T-cell (a type of immune cell attacked by HIV). This study is the first of its kind being done in HIV + persons to see if this investigational drug is safe and effective.

Role: Principal Investigator - .06 calendar

Cost: \$26,559

Duration: 12/15/06 – 12/15/2007

Pfizer
A4001050

A multi-center, open label, expanded access trial of Maraviroc

This is an expanded access protocol for Pfizer's investigational anti-HIV medication, maraviroc which makes the drug available to persons needing new treatment options for their HIV infection. Maraviroc is currently in Phase III clinical trials as a new anti-HIV treatment for HIV infection. The study will make maraviroc available for free to HIV+ persons needing treatment and collecting safety and efficacy data.

Role: Principal Investigator - .06 calendar

Cost: \$17,580

Duration: 02/01/2007 – 01/30/2008

Tibotec Pharmaceuticals - CSRI #201138

A Randomized, Controlled, Open-label Trial to Make TMC114/RTV Available to HIV+ Patients with Limited Treatment Options

The purpose of this study is to look at the long term safety, tolerability, and effectiveness of TMC114 combined with a low dose of Ritonavir (RTV) compared to Kaletra (the current gold-standard protease inhibitor for HIV treatment) when used in subjects with HIV infection.

Role: Principal Investigator - 1% effort

Cost: \$25,350

Duration: 11/11/05 – 12/11/07; 12/12/2007 – 06/11/2008

Pfizer
1026

A Multi-center, Randomized, Double-blind, Comparative Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Zidovudine/Lamivudine versus Efavirenz in Combination with Zidovudine / Lamivudine for the Treatment of Antiretroviral-naïve HIV-1 Infected Subjects

The purpose of this study is to determine the anti-HIV effectiveness of the new anti-HIV drug, UK 427, 857 in combination with other anti-HIV medications against HIV infection in HIV+ patients who have never taken HIV medications and whose HIV is CCR5 tropic (i.e., selects the cell surface marker CCR5 to gain entry into an uninfected cell).

Role: Principal Investigator - .06 calendar

Cost: \$43,483

Duration: 01/01/2005 – 12/31/07; 01/01/2008 – 09/10/2010

Pfizer, Inc.

A400-1078

Phase IIb, Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir vs Atazanavir/Ritonavir + Tenofovir/Emtricitabine for the Treatment of Naïve HIV-Infected Patients with R5 HIV-1

Role: Principal Investigator

Cost: \$32,290

Duration: 4/3/2009 – 4/02/2012

Pfizer

1027

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Novel CCR5 Antagonist, Maraviroc, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-experienced HIV-1 Infected Subjects

The purpose of this study is to determine the effectiveness of the new anti-HIV drug Maraviroc in combination with other anti-HIV medications against HIV infection in treatment-experienced patients whose HIV is CCR5 tropic).

Role: Principal Investigator - .012 calendar

Cost: \$142,901

Duration: 01/01/2005 – 12/31/07; 1/01/2008 – 12/31/2010

INVITED LECTURES (beginning March, 2002)

1. Grand Rounds, Division of Pulmonary/Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, “Update on HIV Research”, Cedars-Sinai Medical Center, Los Angeles, CA, August 27, 2002
2. Grand Rounds, Division of Pulmonary/Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, “Update from the XVth World AIDS Conference” Cedars-Sinai Medical Center, Los Angeles, CA, August 18, 2004
3. Second Annual Tough Decisions Made Easier: Clinical Management of Treatment-experienced HIV + Patients, UCLA Center for AIDS Research & Education (CARE), UCLA-Bradley International Hall, Los Angeles, CA, October 22, 2004

4. Grand Rounds, Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University “Management of Neurologic Complications in the HAART Era”, Chicago, Illinois, October 27, 2004
5. Post ICAAC/Glasgow Conferences Review: “Update on Antiretrovirals Therapy”, AIDS Clinical Research Initiative of America (ACRIA), Plaza Hotel, New York, NY, December 2, 2004
6. Los Angeles Gay & Lesbian Center Visiting Faculty Program: “HIV Protease Inhibitor Update”, Los Angeles, CA, March 4, 2005
7. Department of Medicine House staff Noon Conference: “Methicillin-resistant Staphylococcus aureus”, Department of Graduate Medical Education, Cedars-Sinai Medical Center, Los Angeles, CA, March 28, 2005
8. Grand Rounds, Divisions of Infectious Diseases, Department of Medicine, and Department of Pediatrics, University of Texas at Dallas School of Medicine “Treatment of HIV Infection: New Strategies, New Agents”, Dallas, TX, April 8 and 9, 2005. (two separate lectures; one emphasizing treatment for adult patients, one for pediatric patients)
9. Grand Rounds, Division of Maternal-Child Health, Department of Pediatrics, Keck School of Medicine, University of Southern California (USC), “Update of HIV Antiretroviral Therapy with Emphasis on Prevention of Mother-to-Child Transmission of HIV”, USC School of Medicine/LAC-USC Medical Center, Los Angeles, CA, April 26, 2005
10. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Cedars-Sinai Medical Center, “Update on HIV Treatment and Drug-Drug Interactions”, Los Angeles, CA, April 28, 2005
11. Grand Rounds, Genitourinary and HIV Medicine Department, Royal Free Hospital,” HIV Treatment Guidelines: An American Perspective”, London, UK, August 25, 2005
12. Grand Rounds, Department of Medicine, Royal Free Hospital, “Novel Approach to HIV Vaccine Development”, UK, August 29, 2005
13. European AIDS Clinical Society (EACS) Advanced Course on HIV, “ “HIV Vaccine Development”, Montpellier University, Montpellier, France, August 26-27, 2005
14. Grand Rounds, Department of Medicine, Cedars-Sinai Medical Center “HIV/AIDS: The Global and National Pandemic”, Los Angeles, CA, September 16, 2005
15. Grand Rounds, Division of Infectious Diseases, Department of Pediatrics, Keck School of Medicine, University School of Medicine, “HIV as a Chronic Disease and Associated Complications ”, Children’s Hospital, Los Angeles, CA, October 25, 2005

16. Grand Rounds, Division of Pulmonary/Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, "Progress in HIV Research", Cedars-Sinai Medical Center, Los Angeles, CA, October 26, 2005
17. Didactic Lecture: "HIV Treatment Guidelines", ID Combined Conference, GLAVAMC, Los Angeles, CA, February 14, 2006
18. Los Angeles Physicians AIDS Forum: "Post 13th Conference on Retrovirus & Opportunistic Infections Update", March 7, 2006, Le Meridian Hotel, Los Angeles, CA
19. ID Combined Conference: "Post 13th Conference on Retrovirus & Opportunistic Infections Update", WVAHCS, Los Angeles, CA, March 7, 2006
20. "HIV Treatment: Recent Progress", Physicians from the California Men's Colony at San Luis Obispo, CA, May 30, 2006
21. Invited Lecture for Symposium on Advances in HIV Therapy, "HIV Tropism: Biology of Both Viral and Human Determinants and Therapeutic Applications", Paulista Congress of Infectology, Sao Paulo, Brazil, August 25, 2006
22. Los Angeles Physicians AIDS Forum: "Update from 2006 International AIDS Conference, Hyatt Regency Century Plaza, Los Angeles, CA, September 9, 2006
23. ICAAC Satellite Symposium: Consult with the HIV Experts: "Optimizing HIV Therapy for Treatment-experienced Patients, Moscone Center, San Francisco, CA, September 29, 2006
24. IDSA Satellite Symposium: Emerging Therapies in the Blockade of HIV Binding: "Early Inhibitors: Clinical Progress Thus Far", Sheraton Centre Toronto Hotel, Ontario, Canada, October 11, 2006
25. Continuing Medical Education Program: "Initiating HIV Therapy", Ecotrust Conference Center, Portland, OR, October 24, 2006
26. Infectious Diseases Noon Conference: "New Therapies for HIV Infection", El Rio Community Health Center, Tucson, AZ, February 2, 2007
27. Grand Rounds, Division of Infectious Diseases, Department of Pediatrics, Keck School of Medicine, University of Southern California., "Long Term Safety & Efficacy of Tenofovir-based Regimens Compared to Thymidine-analog Containing Regimens", Children's Hospital Los Angeles, CA, March 27, 2007.
28. Annual Investigators' Meeting of the NIH-sponsored Multi-Site Solid Organ Transplantation Study in HIV+ Patients, "Novel Therapies for HIV Infection: Use in Solid Organ Transplant Patients", Washington, DC, April 29, 2007

29. Grand Rounds, Division of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center, “New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors”, Torrance, CA, July 17, 2007
30. CME Dinner Program: “Current Perspectives on HIV-associated Metabolic and Morphologic Abnormalities”, Boston, MA, August 17, 2007
31. National Minority AIDS Council (NMAC) Annual Conference, Seminar: Special Issues in HIV Care: “New Therapies and Treatments”, Palm Springs, CA, November 8, 2007
32. HIV Grand Rounds, Howard Brown Health Center, “A New Class, A New Option: Understanding CCR5 Antagonists and Maraviroc”, Chicago, IL, January 10, 2008
33. Grand Rounds, Department of Medicine, City of Hope Medical Center, “Strategies for Treatment-Naïve Patients with HIV Infection: When and What to Start?”, Duarte, CA, February 19, 2008
34. Grand Rounds, Division of Pediatric Infectious Diseases, University of Nevada School of Medicine, “Optimizing Antiretroviral Therapy for the Treatment-Experienced Patient: A Case-based Approach”, Reno, NV, February 21, 2008
35. Los Angeles Physicians AIDS Forum: “Update from the 15th Conference on Retroviruses and Opportunistic Infections (CROI)”, InterContinental Hotel, Century City, CA, March 11, 2008
36. HIV Grand Rounds, University Medical Center Wellness Clinic, “Rising to the Challenge: CCR5 Antagonists in Treatment-experienced Patients”, Las Vegas, NV, March 21, 2008
37. HIV Conference Program: “CCR5 Antagonists - A New Era in Patient Management”, Orange County Public Health, Santa Ana, CA, April 2, 2008
38. Grand Rounds, Division of Infectious Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, “Progress in Antiretroviral Therapy”, LAC/USC Medical Center, Los Angeles, CA, May 8, 2008
39. Scientific Meeting on New Trends and New Perspectives for HIV Treatment, Federal University of Rio de Janeiro, “Efficacy and Safety of Maraviroc in HIV+ Patients”, Rio de Janeiro, May, 12 2008
40. 16th Annual State of Texas, Department of HIV/STD Conference, “Protease Inhibitor-based HAART: Predictive Factors for Treatment Success”, Austin, TX, May 18, 2008
41. HIV Minifellowship Program: Current Challenges in the Clinical Management of HAART: “Side Effect Issues and Management Strategies”, Hollywood Roosevelt Hotel, Los Angeles, CA, June 7, 2009

42. Grand Rounds, USC Communicable Diseases Grand Rounds: “HIV in Young Adults: An Often Overlooked Epidemic”, USC Medical Center, Los Angeles, July 11, 2008
43. Grand Rounds, Division of Infectious Diseases, Department of Medicine, “A New Era in Patient HIV Treatment”, Olive View Medical Center, Sylmar, CA, August 15, 2008
44. UCLA Center for AIDS Research and Education (CARE), 6th Annual HIV Symposium – Tough Decisions Made Easier: “Antiretroviral Therapy in the Current Era: Case-Based Panel Discussion”, Renaissance Hotel, Hollywood, CA, October 17, 2008
45. Los Angeles Physicians AIDS Forum, “HIV Highlights of the 2008 ICAAC/IDSA Annual Meeting”, InterContinental Hotel, Los Angeles, CA December 2, 2008
46. Infectious Diseases Grand Rounds, “Post CROI Update: Best Practices in HIV Therapy, Kaiser West Los Angeles, CA, March 26, 2009
47. Grand Rounds, Infectious Diseases Section, Sunnybrook Hospital, “HIV-1 Tropism: How We Can Use it to Treat Human Infection”, Toronto, Canada, March 30, 2009
48. HIV Rounds Noon Lecture: “Viral Tropism: Epidemiology, Natural History, and Therapeutics”, St Michael’s Hospital, Toronto, Canada, March 31, 2009
49. Infectious Diseases Morning Rounds, McMaster University School of Medicine, “Progress in Treating HIV Infection: Using Laboratory Technology to Make Therapeutic Decisions”, McMaster University, Toronto, Canada, April 1, 2009
50. Ottawa HIV Physicians’ Community Consortium, “HIV-1 Tropism: How We Can Use It To Treat Human Infection”, Ottawa, Canada, April 1, 2009
51. The New York Course: HIV Management 2009: “HIV Prevention in Clinical Practice”, Hudson Theatre, New York, May 15, 2009
52. Cedars-Sinai Department of Pharmacy Conference: “Centers for Disease Control STD Treatment Guidelines”, Cedars-Sinai Medical Center, May 27, 2009
53. Grand Rounds, Division of Infectious Diseases, Department of Medicine, SUNY Downstate Medical Center, “A New Era in HIV Patient Management”, Brooklyn, NY, June 24, 2009
54. Grand Rounds, Infectious Diseases Section, Department of Medicine, Beth Israel Medical Center, “Rising to the Challenge: CCR5 Antagonists in Treatment-experienced HIV+ Patients”, Peter Kruger Clinic, New York, NY, June 25, 2009
55. Grand Rounds, Division of Infectious Diseases and HIV Medicine, New York Hospital of Queens, “Viral Tropism and How it can be Used as Treatment for HIV Infection”, Queens, NY, June 26, 2009

56. Grand Rounds, Infectious Diseases Section, Department of Medicine, US Naval Medical Center at Balboa, “Current Considerations for the Management of Patients with HIV Infection”, San Diego, CA, August 14, 2009
57. Plenary Session, Session 1, Basic Science, “HIV Infection: An Inflammatory Disease?”, HIV Congress 2010, Mumbai, India, January 8, 2010
58. Plenary Session, Session 2, Future Therapies, “Stem Cell Therapy for Treatment of HIV Infection”, HIV Congress 2010, Mumbai, India, January 9, 2010
59. Grand Rounds, Division of Infectious Diseases, Department of Medicine, Cedars-Sinai Medical Center, “HIV Infection is an Inflammatory Disease”, Cedars-Sinai Medical Center, February 9, 2010
60. 20th Annual Clinical Care Options for HIV Symposium: Current Opportunities and Continuing Challenges in HIV Care: “Missed Opportunities: Practical Strategies for Enhancing Early HIV Diagnosis and Timely Treatment” - Sheraton Wild Horse Pass, Phoenix, AZ – April 8, 2010.
61. Satellite Symposium, XVIII International AIDS Society (IAS) Conference, “The Art of Orchestration: Achieving Treatment Harmony in HIV Patients- Cardiovascular Disease in HIV Infection”, Vienna Austria, July 18, 2010.
62. Satellite Symposium, ICAAC-2010, “Asked and Answered: Frontline Providers Challenge the Experts on HIV Management Strategies, Boston, MA, September, 13, 2010.
63. Satellite Symposium, ICAAC-2010, “HIV: Assessing the Long-term Consequences of Therapy and Infection”, Boston, MA, September 14, 2010.
64. Seventh Annual St Bernadine Infectious Disease Symposium: “HIV/AIDS: Three Decades of Medical Progress”, St Bernadine Medical Center, San Bernardino, CA, March 26, 2011.
65. 20th Annual HIV/AIDS-On the Front Line: “Challenges of Diagnosing and Treating HIV Infection among Latinos”, University of California at Irvine School of Medicine, Orange, CA, April 27, 2011.
66. Miami Community HIV Physician Forum, “The Overlooked Epidemic: Beyond the Basics: Meeting the Challenges of Caring for Women with HIV Infection”, Miami Beach, FL, September 7, 2011.
67. Los Angeles InterCity HIV Rounds: “Current Clinical Controversies in the Treatment of HIV/AIDS”, Hollywood Presbyterian Medical Center, Los Angeles, CA, February 1, 2012
68. Plenary Session: Current Research Questions: “Is HIV Infection a Cardiovascular Disease Risk Equivalent?”, International HIV Congress 2012, Mumbai, India, March 15- 18, 2012.

69. Plenary Session: HIV Clinical Care: Renal Disease in HIV+ Persons-Diagnosis and Treatment”, International HIV Congress 2012, Mumbai, India, March 15-18, 2012.
70. Department of Medicine Grand Rounds: “Emerging Issues in the Management of HIV Infection”, WVA Medical Center, Los Angeles, CA, June 6, 2012.
71. Third Annual HIV Latina Forum: “Treating Beyond HIV”, Renaissance Sao Paulo Hotel, Sao Paulo, Brazil, June 21 – 23, 2012.
72. Grand Rounds: “Post IAC 2012 Update: Assessing Best Practices in HIV/AIDS Therapy”, Health Care Agency of Orange County, Santa Ana, CA, August 15, 2012
73. Department of Medicine Grand Rounds: “Prevention of HIV Infection-Current Research Progress”, Cedars-Sinai Medical Center, Los Angeles, CA, September 7, 2012.
74. Department of Medicine Grand Rounds: “Curing HIV Infection: Is It Possible?”, Cedars-Sinai Medical Center, Los Angeles, CA, March 29, 2013.
75. Puerto Rico HIV Physician Forum, “HIV Treatment in Latino Persons: Differences in Adherence, Virologic and Immunologic Response to ART?”, San Juan, Puerto Rico, April 19, 2013.
76. Official Satellite Symposium of 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, “Emerging Issues of Aging HIV-seropositive Persons”, Kuala Lumpur, Malaysia, June 28, 2013.

CME-Accredited Programs

1. Foundation for Better Healthcare CME Program: “Fusion Inhibitors: Optimizing Response in Treatment-experienced HIV-infected Patients”, Seattle, WA, January 13, 2004
2. CME Activity: “A New Class, A New Option: Understanding CCR5 Antagonists”, Howard Brown Health Center, Chicago, IL, January 10, 2008
3. CME Activity: “A New Generation of Targets” Understanding Co-Receptor Antagonists”, Milwaukee, WI, January 11, 2008
4. CME Activity for AdvanceMed: HIV Resistance Workshop, Renaissance New York Times Square Hotel, New York, NY, January 25, 2008
5. CME Activity for AdvanceMed: HIV Resistance Workshop, San Francisco, CA, February 22, 2008
6. CME Program: “Current Clinical Controversies in the Treatment of HIV/AIDS”; Case Discussion on Treatment-Experienced Patients: "How many Drugs Does a Patient Need?", Rancho Las Palmas, Rancho Mirage, CA, May 2, 2008

7. CME Program: “Novel Agents for Treatment-Experienced Patients” Faculty Mentoring for Managing Challenging Cases”, Rancho Las Palmas, Rancho Mirage, CA, May 3, 2008
8. CME Program: Simply Speaking HIV – An Expert Educators CME Lecture Series: “Current Clinical Controversies in the Treatment of HIV/AIDS”, Silver Fox, Dallas, TX, May 15, 2008
9. CME Dinner Program: “A New Era in Patient Management”, Simon LA, Los Angeles, CA, May 20, 2008
10. CME Certified Symposium: New Insights into the Use of Protease Inhibitors Across the Treatment Spectrum: Case Scenarios: Participant Polling with Panel Discussion, Inter-Continental Hotel, Los Angeles, CA, June 12, 2008
11. Web-based CME Program: HIV Knowledge Network Study Group, XVII International AIDS Conference: "Highlights of the 2008 IAS", Moderator, August 21, 2008
12. First Care Forums in HIV: “Best Practices Workshops for the Treatment Team”, Millennium UN Plaza Hotel, New York, NY, September 6, 2008.
13. CCO CME-Certified Expert Recap from the 17th International AIDS Conference, Mexico City, August 3-8, 2008: “Update on Timing and Choice of First-Line Therapy”, October 3, 2008
14. CME Dinner Program: Profiles in HIV: In-Depth Analyses and Case Studies of Unique Populations Living with HIV, Los Angeles, CA, January 15, 2009
15. CME Program: First Care Forums in HIV: Best Practices Workshops for the Treatment Team, Madison Hotel, Washington, DC, January 17, 2009
16. CME Program Simply Speaking HIV, Post ICAAC/IDSA 2008 CME Update: “Assessing Best Practices in HIV/AIDS Therapy”, Hollywood Presbyterian Medical Center, Hollywood, CA, January 21, 2009
17. CCO CME Program: Panel Discussion on Management of Antiretroviral Naïve Patients, Loews Hotel Vogue, Montreal, Canada, February 11, 2009
18. CME Program: The HIV Treatment Debate, Renaissance Hotel, Hollywood, CA, March 3, 2009
19. CME Program: “Integrating Resistance Testing into Clinical Practice”, Los Angeles, CA, March 18, 2009

20. CCO CME/CE-Certified Video Module: “Planning and Strategizing for Long-term Success With Antiretroviral Therapy”, April 6, 2009
21. CCO CME/CE-Certified Treatment Update Video Module: CCO HIV: Stay Tuned Evolving Concepts in Antiretroviral Therapy: “Stem Cell Therapy, SWITCHMRK, and HIV-Associated Inflammation”, June 2009
22. CME Harkness Roundtable Program: Current challenges in HIV: Maximizing outcomes Through Case-Based Discussions, West Hollywood, CA, June 17, 2009
23. 5th IAS 2009 Preview from CCO Faculty Experts Audio Preview: “The Impact of Home-Based Compared with Facility-Based HIV Care on Virologic Failure and Mortality: A Cluster Randomized Trial”, July 20, 2009
24. 2009 International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, “Highlights and Overview of Progress in Antiretroviral Therapy, July 19, 2009.
25. CME Dinner Program: “The Graying of an Epidemic: Clinical Considerations of HIV and Aging”, San Francisco, CA, October 20, 2009
26. CME Dinner Program: “Effect of Resistance and Resistance Barriers on ARV Therapy Efficacy”, Beverly Hills, CA, October 21, 2009
27. CME Dinner Program: “The Graying of an Epidemic: Clinical Considerations of HIV and Aging”, New York, NY, October 22, 2009

Cedars-Sinai Medical Center CME Conferences – Chairman & Speaker

1. 5th Annual CSMC World AIDS Day Conference: A Promising Future - Chairman, Cedars-Sinai Medical Center, Hotel Sofitel, Los Angeles, CA, December 4, 2003
2. 6th Annual CSMC HIV/AIDS Update Conference: A Multidisciplinary Approach – Chairman, Cedars-Sinai Medical Center, Le Meridian Hotel, Los Angeles, CA, March 11, 2005
3. 1st CSMC Crystal Methamphetamine Medical Conference (Co-Chair, Organizer & Speaker): “Treatment Options”, Cedars-Sinai Medical Center, Los Angeles, CA, June 23, 2006
4. 7th Annual CSMC HIV/AIDS Medical Update Conference: 25 Years of Old Standards and New Frontiers-A Multidisciplinary Approach - Chairman, Cedars-Sinai Medical Center, Le Meridian Hotel, Los Angeles, CA, September 19, 2006
5. 8th Annual CSMC HIV/AIDS Medical Update Conference: Emerging Issues and Challenges - Chairman, InterContinental Hotel-Century City, Los Angeles, CA, September 28, 2007

6. 9th Annual CSMC HIV/AIDS Conference: “New Therapies, New Patient Populations, and New Global Challenges”, September 26, 2008
7. 10th Annual CSMC HIV/AIDS Conference: “HIV Infections – Inflammation, Prevention and Sex Workers”, September 25, 2009
8. 11th Annual HIV/AIDS Conference: Primary Care and ART Optimization in a Changing Healthcare System, Intercontinental Hotel, Los Angeles, CA, September 24, 2010
9. 12th Annual HIV/ AIDS Conference: Hepatitis C Co-infection, Cardiovascular Disease and Promising Gene Therapies”, SLS Hotel, Los Angeles, CA, September 23, 2011
10. 13th Annual HIV/AIDS Conference: “Comparing First-line Antiretroviral Options, Update on Hepatitis C Treatment, Screening for HIV-associated Neurocognitive Disorders, and Prospects for Curing HIV”, SLS Hotel, Los Angeles, CA, September 28, 2012

PUBLICATIONS/BIBLIOGRAPHY

Research Papers / Peer Reviewed Articles

1. Ahmed RA, Kaplan RP, **Hardy WD**, Feldman E, Pitt H. Bullous pemphigoid and ulcerative colitis. *Int J Dermatol* 21:594-598, 1982.
2. Holland GN, Sakamoto MJ, **Hardy WD**, Sidikaro Y, Krieger AE, Frenkel LM. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome – Use of the experimental drug 9-(2-hydroxyl-1 (hydroxymethyl) ethoxymethyl) guanine (DHPG). *Arch Ophthalmol* 104:1794-1800, 1986.
3. Holland GN, Sidikaro Y, Kreiger AE, **Hardy WD**, Sakamoto MJ, Frenkel LM, Winston DJ, Gottlieb MS, Bryson YJ, Champlin RE, Ho WG, Winters RE, Wolfe PR, Cherry JD. Treatment of cytomegalovirus retinopathy with ganciclovir. *Ophthalmology* 94:815-823, 1987.
4. Fay MT, Freeman WR, Wiley CA, **Hardy WD**, Bozzette S. Atypical retinitis in patients with the acquired immunodeficiency syndrome. *Am J Ophthalmol* 105:483-490, 1988.
5. Fischl MA, Richman DD, Causey DM, Grieco MH and the AZT Collaborative Working Group-**Hardy, WD**. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. *JAMA* 262:2405-2410, 1989.
6. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ and UCLA CMV Retinopathy Study Group- **Hardy, WD**. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. *Arch Ophthalmol*. Dec; 107(12):1759-66, 1989.

7. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers M, Booth D, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, **Hardy WD**, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. *N Engl J Med* 322:941-949, 1990.
8. Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L, Sonke RL, Spector SA, Valentine F, Pettinelli C, Richman DD, ACTG 004 Investigators-**Hardy, WD**. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. *Ann Intern Med*. Jul 15;113(2):111-7, 1990.
9. Engstrom RE Jr, Holland GN, **Hardy WD**, Meiselman HJ. Hemorheologic abnormalities in patients with human immunodeficiency virus infection and ophthalmic microvascularopathy. *Am J Ophthalmol* 109:153-161, 1990.
10. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, **Hardy WD**, Dolin R, Powderly WG, Allan JD, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. *Ann Intern Med* 112:727-737, 1990.
11. **Hardy WD**. Combined ganciclovir and recombinant human granulocyte- macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. *J Acquir Immune Defic Syndr* 1:S22-28, 1991.
12. Wu AW, Rubin HR, Mathews WC, Ware JE Jr, Brysk LT, **Hardy WD**, Bozzette SA, Spector SA, Richman DD. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with HIV infection. *Med Care* 29:786-798, 1991.
13. Janoff EN, **Hardy WD**, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity and affinity of antigen-specific IgG. *J Immunol* 147:2130-2135, 1991.
14. **Studies of the Ocular Complications of AIDS (SOCA) Research Group**. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. *Studies of Ocular Complications of AIDS Research Group*, in collaboration with the AIDS Clinical Trials Group. *N Engl J Med*. Jan 23;326(4):213-20, 1992.
15. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, **Hardy WD**, et al and the NIAID AIDS Clinical Trials Group. A controlled trial comparing zidovudine with didanosine in human immunodeficiency virus infection. *N Engl J Med* 327:581-587, 1992.
16. **Studies of the Ocular Complications of AIDS (SOCA) Research Group**. *Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial*: 1.

- Rationale, design, and methods. AIDS Clinical Trials Group (ACTG). Control Clin Trials. Feb;13(1):22-39, 1992.
17. Bass HZ, **Hardy WD**, Mitsuyasu RT, et al. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. *J Acquir Immune Def Syndr* 5:215-221, 1992.
 18. Bass HZ, **Hardy WD**, Mitsuyasu RT, Wang YX, Cumberland W, Fahey JL. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. *J Acquir Immune Defic Syndr* 5:890-897, 1992.
 19. **Hardy WD**. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. *Am J Med* 14;92(2A):30S-35S, 1992.
 20. Bass HZ, Nishanian P, **Hardy WD**, Mitsuyasu RT, Esmail E, Cumberland W, Fahey JL. Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. *Clin Immunol Immunopathol* 64:63-70, 1992.
 21. Recommendations for prophylaxis against *Pneumocystis carinii* pneumonia for adults and adolescents infected with human immunodeficiency virus (Hardy WD-. *MMWR Recomm Rep.* 1992 Apr 10;41(RR-4):1-11. PMID: 1348843.
 22. U. S. Public Health Service Task Force on Prophylaxis against *Pneumocystis Pneumonia* in HIV Infection (**Hardy WD** – member). Recommendations for prophylaxis against *Pneumocystis carinii* pneumonia for adults and adolescents infected with HIV. *JAMA* 267:2294-2299, 1992.
 23. **Hardy WD**, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, et al. A controlled trial of trimethoprim- sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. *N Engl J Med* 327:1842-1848, 1992.
 24. Jacobson MA, Causey D, Polsky B, **Hardy WD**, Chown M, Davis R, O'Donnell JJ, Kupper-Mann B, Heinemann M-H, Holland G, Mills J, Feinberg JE. Randomized dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS (ACTG 015/915). *J Inf Dis* 168:444-448, 1993.
 25. Wu AW, Rubin HR, Mathews WC, Brysk LM, Bozzette SA, **Hardy WD**, Atkinson JH, Grant, I, Spector SA, McCutchan JA, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. *J Acquir Immune Defic Syndr* 6:452-458, 1993.
 26. **Hardy WD**, Spector S, Polsky B, Crumpacker C, van der Horst C, Holland G, Freeman W, Heinemann MK, Sharuk G, Klystra J, Chown M and the ACTG 073 Study Team.

- Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. *Eur J Clin Microbiol Infect Dis* 2:34-40, 1994.
27. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT, ... **Hardy, WD**, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. *JAMA* 1994 Aug 10;272(6):437-42.
 28. **Studies of the Ocular Complications of AIDS (SOCA) Research Group**. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. *Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology*. Jul;101(7):1250-61, 1994.
 29. Fischl MA, Lim L, Richman DD, Pettinelli C, LoFaro ML, Balfour HH, **Hardy WD**, Dolin R, Para F, Carey JT, Allan JD, Powderly WG, Merigan TC, Wong B, Collier AC. The long-term safety and efficacy of zidovudine in the treatment of patients with mildly symptomatic human immunodeficiency virus type I (HIV) infection: The potential value of early versus later treatment interruption. *Ann Intern Med* 1994.
 30. **Studies of the Ocular Complications of AIDS (SOCA) Research Group**. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. *Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med*. Jan 9;155(1):65-74, 1995.
 31. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz I, Plasse TF, Shepard KV, (Study Team, **Hardy WD**). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symp Management* 10(2):89-97, 1995.
 32. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng T-C, Fischl MA, Collier AC, Phair JP, Hirsch MS, **Hardy WD**, Balfour HH, Reichman RC. A comparison of immediate versus deferred zidovudine in asymptomatic HIV-infected subjects with CD4 cell counts of 500 per microliter or greater. *N Engl J Med* 1995 Aug 17;333(7):401-7.
 33. Petersen FA, Ramirez-Ronda CH, **Hardy WD**, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. *J Infect Dis* 171 (Suppl 2):S131-139, 1995.
 34. Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, **Hardy WD**, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. *AIDS Clinical Trials Group. Arch Intern Med* 155:961-974, 1995.

35. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Arch Ophthalmol. Jul;114(7):848-55, 1996.
36. Freedberg KA, **Hardy WD**, Holzman RS, Tosteson AN, Craven DE. Validating literature-based models with direct clinical trial results: the cost- effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making 16:29-35, 1996.
37. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the cytomegalovirus retreatment trial. Arch Ophthalmol 114(1):23-33, 1996.
38. Wu AW, Jacobson DL, Berzon RA, Revicki DA, van der Horst C, Fichtenbaum CJ, Saag MS, Lynn L, **Hardy WD**, Feinberg J. The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Qual Life Res, Jan:6(1): 3-10, 1997.
39. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med. Feb 15;126(4):264-74. 1997.
40. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis. Jul;176(1):50-8, 1997.
41. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). Am J Ophthalmol. Jul;124(1):61-70, 1997.
42. **Studies of the Ocular Complications of AIDS (SOCA) Research Group.** Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Am J Ophthalmol. Aug;124(2):141-57, 1997.
43. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, **Hardy WD**, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. Randomized, controlled study of the

- safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. *J Acquir Immune Defic Syndr Hum Retrovir* 17:339- 344, 1998.
44. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dietrich DT, **Hardy WD**, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society – USA. *Arch Intern Med* 158:957-969, 1998
 45. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, **Hardy WD**, Beall G, Cooper R, Murphy R, Basgoz L, Ng E, Deeks S, Winslow D, Toole J, Coakley D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. *JAMA* 282:2305-12, 1999.
 46. Pollard RB, Peterson D, **Hardy WD**, Pottage J, Murphy RL, Gathe J, Beall G, Rutkiewicz V, Reynolds L, Cross AP, Dunkle LM. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm³. *J Acquir Immune Defic Syndr*. Sep 1;22(1):39-48, 1999
 47. Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K, Martin- Munley S, **Hardy WD**. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: A phase I/II study. *J Acquir Immune Defic Syndr* 21:301-306, 1999
 48. **Studies of Ocular Complications of AIDS Research Group** in collaboration with the AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. *AIDS* 2000 Jul 28;14(11):1571-81.
 49. Jacobson MA, **Hardy WD**, Connick E, Watson J, DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4+ cells/microliter. *J Infect Dis* Oct; 182(4): 1070-6, 2000.
 50. Holbrook JT, Davis MD, Hubbard LD, Martin BK, Holland GN, Jabs DA, Gilpin AK, Meinert C, Reshef DS, **Studies of the Ocular Complications of AIDS (SOCA) Research Group- Hardy, WD**. Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. *Studies of Ocular Complications of AIDS Research Group*. *Arch Ophthalmol*. Sep;118(9):1196-204, 2000.
 51. Goodgame JC, Pottage JC, Jablonowski H, **Hardy WD**, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naïve adults. Amprenavir PROAB3001 International Study Team. *Antivir Ther* 5: 215-225, 2000.

52. **Studies of Ocular Complications of AIDS (SOCA) Research Group.** The AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. *Am J Ophthalmol.* Apr;131(4):457-67, 2001.
53. Lalezari JP, Friedberg DN, Bissett J, Giordano MF, **Hardy WD**, Drew WL, Hubbard LD, Buhles WC, Stempien MJ, Georgiou P, Jung DT, Robinson CA; Roche Cooperative Oral Ganciclovir Study Group. High-dose oral ganciclovir treatment for cytomegalovirus retinitis. *J Clin Virol.* 2 Feb;24(1- 2):67-77, 2002.
54. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ; Valganciclovir Study Group-**Hardy, WD.** A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. *N Engl J Med.* Apr 11;346(15):1119-26. 2002.
55. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D, Studies of the Ocular Complications of AIDS (SOCA) Research Group- **Hardy, WD.** Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. *Arch Ophthalmol.* Jan;121(1):99-107, 2003.
56. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H., MOTIVATE Study Teams- **Hardy WD.** Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med* Oct 2:359(14): 1429-41, 2008.
57. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AIM, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE Study Teams- **Hardy WD.** Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med* Oct 2:359(14): 1442-55, 2008.
58. Holland GN, Vaudaux JD, Jeng SM, Yu F, Goldenberg DT, Folz IC, Cumberland WG, McCannell CA, Helm CJ, **Hardy WD,** UCLA Retinitis Study Group. Characteristics of untreated AIDS-related cytomegalovirus retinitis: Part 1- findings before the era of highly active antiretroviral therapy (1988 – 1994). *Am J Ophthalmol,* Jan: 145(1): 5-11, 2008.
59. Stein JH, Hadigan CM, Brown TT, Chadwick E, Feinberg J, Friis-Moller N, Ganesan A, Glesby MJ, **Hardy D,** Kaplan RC, Kim P, Lo J, Martinez E, Sosman JM: Working Group 6. Prevention strategies for cardiovascular diseases in HIV-infected patients. *Circulation* Jul 8:118 (2): e54-60, Epub 2008 Jun 19, 2008

60. Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, Dove L, Roland M, Florman S, Blumberg E, Stosor V, Jayaweera DT, Huprikar S, Fung J, Pruett T, Stock P, Ragni M and Solid Organ Transplantation in HIV: Multi-Site Study Investigators-**Hardy WD**. MELD score is an important predictor of pre-transplantation mortality in HIV-infected liver transplant candidates. *Gastroenterology*. Jan;138(1):159-64, 2010. doi: 10.1053/j.gastro.2009.09.053. Epub 2009 Sep 30.
61. Miyasaki Y, Nichols WS, Morgan MA, Kwan JA, Van Benschoten MM, Kittell PE, **Hardy WD**. Screening of herbal extracts against multi-drug resistant *Acinetobacter baumannii*. *Phytother Res*. Aug;24(8):1202-6, 2010. doi: 10.1002/ptr.3113.
62. **Hardy WD**, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajjic N, Goodrich J. Two year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96 week combined analysis of MOTIVATE 1 and 2. *J Acquir Immune Defic Syndr* 2010;55:558–564, Aug 11, 2011[Epub ahead of print] .
63. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pullit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O’Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gullick RM, Shikum CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaud HJ, Agan B, Agarwal S, Ahem RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson BK, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czarloski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerlin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, **Hardy WD**, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, JohnsonKL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killan RK, Kim AU, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Libre JM, Liquori MA, Little SJ, Liu AU, Lopez AJ, Loufty MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Meyer- Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH,

- Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Paviatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schultemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi I, Vega VM, Velkley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*, Dec 2010.10:330 (6010): 1551-7, Epub Nov 4, 2010.
64. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F, International HIV Controllers Study Group- **Hardy WD**, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 2 diabetes and HIV-1 immune control. *Am J Hum Genet*, Jan; 86 (1) 88-92, 2010
65. Vrouenraets S, Wit F, Fernandez Garcia E, Moyle G, Jackson A, Allavena C, Raffi F, Jayaweera D, Mauss S, Katlama C, Fisher M, Slama L, **Hardy WD**, Dejesus E, van Eeden A, Reiss P; for the BASIC study group. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. *HIV Med*. 2011 Nov;12(10):620-631. doi: 10.1111/j.1468-1293.2011.00941.x. Epub 2011 Aug 7. PMID 21819530
66. Harbell J, Fung J, Nissen N, Olthoff K, Florman SS, Hanto DW, Light J, Bartlett ST, Tzakis AG, Pearson TC, Barin B, Roland ME, Stock PG; Solid Organ Transplant in HIV: Multi-site Study Investigators-**Hardy WD**. Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. *Surgery*. Sep;152(3):376-81, 2012. doi: 10.1016/j.surg.2012.06.012.
67. Kyme P, Thoennissen NH, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO, Lee K, Müller-Tidow C, Berdel WE, **Hardy WD**, Gombart AF, Koeffler HP, Liu GY. C/EBP ϵ mediates nicotinamide-enhanced clearance of *Staphylococcus aureus* in mice. *J Clin Invest*. 2012 Sep 4;122(9):3316-29. doi: 10.1172/JCI62070. Epub 2012 Aug 27. Erratum in: *J Clin Invest*. 2012 Nov;122(11):4301.
68. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Millis JM, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odum J, Fox L, Stock PG; Solid Organ Transplantation in HIV: Multi-Site Study Investigators-

- Hardy WD.** Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. *Liver Transpl.* Jun;18(6):716-26, 2012. doi: 10.1002/lt.2341.
69. Ellefsen-Lavoie, Rockstroh J, Pollard R, Pantaleo G, Podzamczar D, Asmuth D, van Lunzen J, Arastéh K, Schürmann D, Peters B, Clotet B, **Hardy WD**, et al. Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine. *Retrovirology* 2012 9 (Suppl 2):O66.
70. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI; **Hardy WD**- International HIV Controllers Study . Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. *Hum Mol Genet.* 2012 Oct 1;21(19):4334-47. doi: 10.1093/hmg/dds226. Epub 2012 Jun19.
71. Raffi F, Rachlis A, Stellbrink HJ, **Hardy WD**, Torti C, Orkin C, Bloch M, Podzamczar D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, on behalf of the SPRING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. *Lancet* 12: 1853-4, Jan 7, 2013
72. Ragni MV, Devera ME, Roland ME, Wong M, Stosor V, Sherman KE, **Hardy WD**, Blumberg E, Fung J, Barin B, Stablein D, Stock PG. Liver transplant outcomes in HIV+ haemophilic men. *Haemophilia.* 2013 Jan;19(1):134-40. doi: 10.1111/j.1365-2516.2012.02905.x. Epub 2012 June
73. Chu D, Hu S, Wang W, Subramanian A, Chung E, Kanagavel V, Sinha S, Jalali Z, **Hardy WD**, French S, Arumugaswami V. Systematic analysis of cis- acting replication elements in the protein encoding region of hepatitis C virus genome. *J Virol.* 2013 May;87(10):5678-96. doi: 10.1128.JVI.00840-12. Epub2013 Mar13.
74. Miyasaki Y, Rabenstein JD, Rhea J, Crouch M-L , Mocek UL, Kittell PE, Morgan MA, Nichols WS, Van Benschoten MM, **Hardy WD**, Liu GY. Isolation and characterization of antimicrobial compounds in plant extracts against multidrug-resistant *Acinetobacter baumannii*. *PLOS ONE.* 2013 April 22, 8(4): e61594. doi:10.1371/journal.pone.0061594.
75. Goodkin K, López E, Hardy DJ, **Hardy WD**. Neurocognitive Decline in HIV Infection. *Psychiatr Ann.* 2013; 43: 204-211. doi: 10.3928/00485713-20130503-04; <https://doi.org/10.3928/00485713-20130503-04>.
76. Bahirwani R, Barin B, Olthoff K, Stock P, Murphy B, Rajender Reddy K; Solid Organ Transplantation in HIV: Multi-Site Study Investigators- **Hardy WD**. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the national institutes of health multi-site study. *Liver Transpl.* Jun;19(6):619-26, 2013. doi: 10.1002/lt.23648

77. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade- Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team-**Hardy WD**. Dolutegravir versus raltegravir in antiretroviral- experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet*. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
78. Tellalian D, Maznavi K, Bredeek F, **Hardy WD**. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. *AIDS Patient Care STDS*. 2013 Oct;27(10):553-9. doi: 10.1089/apc.2013.0173. Epub 2013 Sep 20.
79. Gulick R, Fätkenheuer G, Burnside R, **Hardy WD**, Nelson M, Goodrich J, Mukwaya G, Heera J, Portsmouth S. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients. *J Acquir Immune Defic Syndr*. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a
80. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamecz D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, **Hardy WD**, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2014 Feb 10: S1473-3099(13)70343-8. doi: 10.1016/S1473-3099(13)70343-8. [Epub ahead of print].
81. Stock PG, Barin B, Hatano H, Rogers RL, Roland ME, Lee TH, Busch M, Deeks SG; for Solid Organ Transplantation in HIV Study Investigators-(**Hardy, WD**). Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. *Am J Transplant*. 2014 May;14(5):1136-41. 2014. PMID:24698537.
82. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; for PHOTON-1 Investigators (**Hardy WD**). Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. *JAMA*. 2014 Jul 23-30;312(4):353-61. doi:10.1001/jama.2014.7734. PMID 25038354.
83. Nelson MD, LaBounty T, Szczepaniak LS, Szczepaniak E, Smith L, John LS, Li D, Tighiouart M, Li Q, Dharmakumar R, Yumul R, Sannes G, Fan Z, **Hardy WD**, Conte AH. Cardiac steatosis and left ventricular dysfunction is associated with exposure to human immunodeficiency virus highly active antiretroviral therapy: a 3-Tesla cardiac magnetic resonance imaging study. *J American College Cardiology-Imaging* 2014;63:923-926.

84. Diaz-Zamudio M, Dey D, LaBounty T, Nelson M, Fan Z, Szczepaniak L, Hsieh P-C, Rajani R, Berman D, Li D, **Hardy WD**, Conte AH. Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of HAART exposure in patients with HIV infection. *J Cardiovasc Magn Reson*. Oct 31;17:91. 2015. PMID:26520571.
85. LaBounty, **Hardy WD**, Fan Z, Yumul R, Li, D, Dharmakumar R, Conte AH. Patients with human immunodeficiency virus (HIV) on chronic treatment have increased carotid artery wall thickness on magnetic resonance imaging. *HIV Med*. 2016 Aug;17(7):516-23. doi: 10.1111/hiv.12351. Epub 2015 Dec 3. PMID:26634886
86. Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, Olthoff K, Simon D, **Hardy WD**, Beatty G, Stock PG; HIVTR Study Team. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. *AIDS*. 2016 Jan 28;30(3):435-44. PMID:26765937.
87. Halec G, Waterboer T, Brenner N, Butt J, **Hardy WD**, D'Souza G, Wolinsky S, Macatangay BJ, Pawlita M, Detels R, Martínez-Maza O, Hussain SK. Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma. *J Acquir Immune Defic Syndr*. 2018 Nov 20. doi: 10.1097/QAI.0000000000001916. [Epub ahead of print]
88. Wohl DA, Brinson C, Hicks C, Shalit P, **Hardy WD**, et al. Real-world insights into quality improvement across 11 HIV clinics in the United States. *Open Forum Infect Dis*. 2018;5(Suppl 1):S547–S548. doi:10.1093/ofid/ofy210.1561
89. Rosen JG, Malik M, Cooney EE, Wirtz AL, Yamanis T, Lujan M, Cannon C, **Hardy WD**, Poteat T. Antiretroviral treatment interruptions among black and latina transgender women living with HIV: characterizing co-occurring, multilevel factors using the gender affirmation framework. *AIDS Behav*. 2019 Jul 1. doi: 10.1007/s10461-019-02581-x. [Epub ahead of print].
90. Cox J, Gutner C, Kronfli N, Lawson A, Robbins M, Nientker L, Ostawal A, Barber T, Croce D, **Hardy D**, Jessen H, Katlama C, Mallolas J, Rizzardini G, Alcorn K, Wohlfeiler M, Le Fevre E. A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review. *PLoS One*. 2019 Aug 19;14(8):e0220060. doi: 10.1371/journal.pone.0220060. PMID: 31425524; PMCID: PMC6699703.
91. Macias Gil R, **Hardy WD**. Spectrum of diversity in today's infectious diseases workforce: it's much broader and brighter than you think. *J Infect Dis*. 2019 Aug 20;220(Suppl 2):S42-S49. doi: 10.1093/infdis/jiz242. PMID: 31430383.
92. Goldstein DA, Sarkodie E, **Hardy WD**. Transgender and nontrans patients do not receive statistically different quality primary care at Whitman-Walker Health, 2008-2016.

Transgend Health. 2019 Sep 23;4(1):200-208. doi: 10.1089/trgh.2019.0022. PMID: 31552291; PMCID: PMC6757235.

93. Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, **Hardy WD**, Arrington-Sanders R, Lujan M, Yamanis T. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among black and latina transgender women. *J Acquir Immune Defic Syndr*. 2019 Oct 1;82(2):131-140. doi: 10.1097/QAI.0000000000002112. PMID: 31180995.
94. Wirtz AL, Poteat T, Radix A, Althoff KN, Cannon CM, Wawrzyniak AJ, Cooney E, Mayer KH, Beyrer C, Rodriguez AE, Reisner SL; an American Cohort To Study HIV Acquisition Among Transgender Women Investigators (LITE-**Hardy, WD**). American Cohort to Study HIV Acquisition Among Transgender Women in High-Risk Areas (The LITE Study): Protocol for a Multisite Prospective Cohort Study in the Eastern and Southern United States. *JMIR Res Protoc*. 2019 Oct 3;8(10):e14704. doi: 10.2196/14704. PMID: 31584005; PMCID: PMC6802485.
95. Patel S, Hanajiri R, Grant M, Saunders D, Van Pelt S, Keller M, Hanley PJ, Simon G, Nixon DF, **Hardy WD**, Jones RB, Bollard CM. HIV-specific T cells can be generated against non-escaped T cell epitopes with a GMP-compliant manufacturing platform. *Mol Ther Methods Clin Dev*. 2019 Oct 11;16:11-20. doi: 10.1016/j.omtm.2019.10.001. PMID: 31720305; PMCID: PMC6838524.
96. Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CC, **Hardy WD**, Safrit JT, Jones RB. Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal. *J Virol*. Feb 2020, JVI.01845-19; DOI:10.1128/JVI.01845-19.
97. Ren Y, Huang SH, Patel S, Conce Alberto WD, Magat D, Ahimovic DJ, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R³, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon CM, **Hardy WD**, Bosque A, Bollard CM, Jones RB. BCL-2 antagonism sensitizes cytotoxic t cell-resistant HIV reservoirs to elimination ex vivo. *J Clin Invest*. 2020 Feb 6. pii: 132374. doi: 10.1172/JCI132374. [Epub ahead of print].
98. Goldstein D, **Hardy WD**, Monroe A, Hou Q, Hart R, Terzian A; DC Cohort Executive Committee. Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis. *BMC Public Health*. 2020 Apr 16;20(1):509. doi: 10.1186/s12889-020-08631-7. PMID: 32299421; PMCID: PMC7164348.
99. Koren DE, Scarsi KK, Farmer EK, Cha A, Adams JL, Pandit NS, Chang J, Scott J, **Hardy WD**. A Call to Action: The Role of Antiretroviral Stewardship in Inpatient Practice, a Joint Policy Paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. *Clin Infect Dis*. 2020 May 23;70(11):2241-2246. doi: 10.1093/cid/ciz792. PMID: 32445480; PMCID: PMC7245143.

100. de Los Rios P, Okoli C, Punekar Y, Allan B, Muchenje M, Castellanos E, Richman B, Corbelli GM, **Hardy WD**, Young B, Van de Velde N. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. *Prev Med.* 2020 Jun 25:106182. doi: 10.1016/j.ypmed.2020.106182. Epub ahead of print. PMID: 32593732.
101. Okoli C, Van de Velde N, Richman B, Allan B, Castellanos E, Young B, Brough G, Eremin A, Corbelli GM, Mc Britton M, **Hardy WD**, de Los Rios P. Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries. *Sex Transm Infect.* 2020 Jul 30:sextrans-2020-054551. doi: 10.1136/sextrans-2020-054551. Epub ahead of print. PMID: 32732335.
102. Lin CA, Behrens PH, Paiement G, **Hardy WD**, Mirocha J, Rettig RL, Kiziah HL, Rudikoff AG, Hernandez Conte A. Metabolic factors, and post-traumatic arthritis may influence the increased rate of surgical site infection in patients with human immunodeficiency virus following total hip arthroplasty. *J Orthop Surg Res.* 2020 Aug 12;15(1):316. doi: 10.1186/s13018-020-01827-y. PMID: 32787972; PMCID: PMC7425402.
103. de Los Rios P, Okoli C, Castellanos E, Allan B, Young B, Brough G, Muchenje M, Eremin A, Corbelli GM, McBritton M, **Hardy WD**, Van de Velde N. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. *AIDS Behav.* 2020 Oct 7. doi: 10.1007/s10461-020-03055-1. Epub ahead of print. PMID: 33026574.

Research Papers – Peer Reviewed (in press)

Manuscripts – Peer Reviewed (submitted)

1. **Hardy WD**, Ren, S, Liu C, Folks T, Chen I. Recombinant foamy virus (FV) vectors persistently express high levels of HIV-1 p24 antigen: potential for HIV vaccine development. (Submitted to *Retrovirology*)
2. **Hardy WD**, Ren S, Folks T, Chen I: Recombinant foamy virus vectors integrate HIV-1 gag into murine PBMCs and elicit immune responses to expressed gag protein. (Submitted to *AIDS Research and Human Retroviruses*)

Text Books Edited

1. *Fundamentals of HIV Medicine for the HIV Specialist*, 2007 Edition. Washington, DC: American Academy of HIV Medicine. 2007: [pages 1-1163]. **US Core Curriculum Committee**
2. *Fundamentals of HIV Medicine for the HIV Specialist -Electronic Update*, 2008 Edition. Washington, DC: American Academy of HIV Medicine. 2008: [pages 1-350]. **Editor-in-Chief**

3. *Fundamentals of HIV Medicine for the HIV Specialist, -Electronic Update*, 2010 Edition. Washington, DC: American Academy of HIV Medicine. 2010: [pages 1-300]. **Editor-in-Chief**
4. *Fundamentals of HIV Medicine for the HIV Specialist*, 2012 Edition. Washington, DC: American Academy of HIV Medicine. 2012: [pages 1-860]. **Editor-in-Chief**
5. *Fundamentals of HIV Medicine for the HIV Specialist*, 2017 Edition. Oxford Academic Press. 2017: [pages 1-616]. **Editor-in-Chief**. DOI:1093/med/9780190493097.001 .0001.
6. *Fundamentals of HIV Medicine for the HIV Specialist*, 2019 Edition. Oxford Academic Press. 2019: [pages 1-584]. **Editor-in-Chief**. ISBN: 9780190936044. DOI:

Book Chapters

1. Gottlieb MS, Wolfe PR, Fahey JL, Knight S, **Hardy WD**, Eppolito L, Ashida E, Patel A, Beall G, Sun N. The syndrome of persistent generalized lymphadenopathy: experience with 101 patients. In: *AIDS-Related Syndromes*. Sudhir Gupta, ed, Plenum Publishing, pp:85-91, 1985.
2. **Hardy WD**. Prophylaxis of AIDS-related opportunistic infections (OIs). In: *AIDS Clinical Review*, Volberding PA and Jacobson MA, eds. New York: Marcel Dekker, pp 125-150, 1989.
3. **Hardy WD**. Recent advances and future strategies for prophylaxis of AIDS-related opportunistic infections. In: *Treatment Strategies in Oncology: Current Issues in the Management of Patients with HIV Infection*, Krown SE and Borden EC, eds. London: Mediscript, pp 43-77, 1991.
4. **Hardy WD** and the ACTG 073 Treatment Group. Combined ganciclovir and granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of cytomegalovirus retinitis in AIDS patients: Rational for and preliminary results from a phase II, randomized trial (ACTG 073). In: *Ganciclovir Therapy for Cytomegalovirus Infection*, Spector S, ed. New York: Marcel Dekker, pp 197-214, 1991.
5. **Hardy WD**. Prophylaxis of AIDS-related opportunistic infections (OIs): Current status and future strategies. In: *AIDS Clinical Review*, Volberding PA and Jacobson MA, eds. New York: Marcel Dekker, pp 145-180, 1991.
6. Moe AA, **Hardy WD**. *Pneumocystis carinii* in the HIV-seropositive patient. *Infect Dis Clin North Am* 8:331-364, 1994.
7. **Hardy WD**. Natural History of HIV Infection and Disease. In: *Surgical Problems in the AIDS Patient*. Wilson SE and Williams RA, eds. New York: Igaku-Shoin, Ltd., pp 17- 29, 1994.

8. Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, **Hardy WD**: Neurocognitive Disorders in the HAART Era. Chapter 1. In: K Goodkin, P Shapshak, and A Verma (eds.). *The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment*. Washington, DC: ASM Press, July, pp 3-27, 2008
9. Goodkin K, Concha M, Molina R, Lopez E, Zheng W, Jamieson B, Asthana D, **Hardy WD**: Older Age and Neuro-AIDS Conditions in the HAART Era. Chapter 33. In: K Goodkin, P Shapshak, and A Verma (eds.). *The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment*. Washington, DC: ASM Press, pp 473-486, July 2008.

Editorials

1. **Hardy D**. The disconnect between HIV and STDs: why screening for STDs should take on a renewed focus. *Clinical Issues in HIV Medicine, Clin Infect Dis* 1:i-iv, 2008.
2. **Hardy D**. Delivering “real world” HIV prevention messages to our patients. *Clinical Issues in HIV Medicine, Clin Infect Dis* 1:vii-viii, 2009.
3. **Hardy D**. A case study in changing unsafe sex behavior: A Latino man who has sex with men and women. *Clinical Issues in HIV Medicine, Clin Infect Dis* 1: i-iii, 2010.
4. **Hardy WD**. Analytical treatment interruptions and human immunodeficiency virus cure research: seizing the opportunity while maintaining safety and respect, *Clin Infect Dis*. ciz421, <https://doi.org/10.1093/cid/ciz421>. [Epub ahead of print: 16 May 2019].

Reviews

1. Balfour HH Jr, Drew WL, **Hardy WD**, Heinemann MH, Polsky B. Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. *J Acquir Immune Def Syndr* 5(Suppl 1):S37-44, 1992.
2. **Hardy WD**. Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease. *AIDS: Nov: 10 Suppl 1*:S3-5, 1996.
3. **Hardy WD**. Management strategies for patients with cytomegalovirus retinitis. *J Acquir Immune Syndr Hum Retrovirol* 14 (Suppl 1): S7-12, 1997.
4. **Hardy WD**, Hitt RS. Designing salvage antiretroviral regimens. Some basic guidelines and use of resistance testing. *Postgrad Med* 107:149-153, 157-160, 2000.
5. Rockstroh JK, **Hardy WD**. Antiretroviral therapy in coinfecting patients: viral hepatitis and tuberculosis. *Curr Opin HIV AIDS* 1:442-448, 2006.
6. Robertson K, Liner J, Hakim J, Sankale JL, Grant I, Letendre S, Clifford D, Diop AG, Jaye A, Kanmogne G, Njamnshi A, Langford TD, Weyessa TG, Wood C, Banda M,

Hosseini-pour M, Sacktor N, Nakasuja N, Bangirana P, Paul R, Joska J, Wong J, Boivin M, Holding P, Kammerer B, Van Rie A, Ive P, Nath A, Lawler K, Adebamowo C, Royald W 3rd, Joseph J, NeuroAIDS in Africa Conference Participants- **Hardy WD**. NeuroAIDS in Africa. *J Neurovirology* Jun; 16 (3): 189-202, 2010.

7. Wasmuth J-C, Rockstroh, JK, **Hardy WD**. Drug safety evaluation of maraviroc for the treatment of HIV-infection. *Expert Opin. Drug Saf.* 11(1):161-174, PMID 22118500, Jan 2012.
8. Conte AH, Esmailian F, Labounty T, Lubin L, **Hardy WD**, Yumul R. The Patient with the Human Immunodeficiency Virus-1 in the Cardiovascular Operative Setting. *J Cardiothorac Vasc Anesth.* 2012 Aug 21. [Epub ahead of print]. PMID: 22920840.
9. Rockstroh JK, Hardy WD. Current treatment options for hepatitis C patients co-infected with HIV. *Expert Rev Gastroenterology Hepatology.* 2016 DOI: 10.1586/17474124.2016.1145545

Case Reports

1. **Hardy WD**, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. *Am J Med* 87:329-331, 1989.
2. Panosian CB, Cohen L, Bruckner D, Berlin G, **Hardy WD**. Fever, leukopenia and a cutaneous lesion in a man who had recently traveled in Africa. *Rev Infect Dis* 13:1131-1138, 1991.
3. Lucatorto FM, Franker C, **Hardy WD**, Chafey S. Treatment of refractory oral candidiasis with fluconazole. A case report. *Oral Surg Med Oral Pathol* 71:42-44, 1991.
4. **Hardy WD**, Daar ED, Sokolov RT Jr, Ho DD. Acute neurologic deterioration in a young man. *Rev Infect Dis* 13:745-750, 1991.
7. Palys EE, Li J, Gaut PL, **Hardy WD**. Case Report: Tricuspid valve endocarditis with group B streptococcus after an elective abortion: the need for new data. *Infect Dis Obstet & Gynecol* 14(3):43-53, 2006.
8. Douglas JJ, Brown SR, Martowski A, **Hardy WD**. Near fatal fellatio: a case of necrotizing fasciitis after oral sex. *International STD Research & Reviews*, ISSN: 2347- 5196, Vol.: 2, Issue.: 2 (July-December) 2014.
9. Conte, AH, Kittleson M, Dilibero D, Hardy WD., Kobashigawa J, Esmailian F. Successful orthotopic heart transplantation and immunosuppressive management in 2 human immunodeficiency virus-seropositive patients. *Tex Heart Inst J* 2016;43(1):69-74.

Website Publications

1. **Hardy WD**. Cytomegalovirus – Advances in treatment and prevention. Medscape HIV/AIDS 2(1), www.medscape.com/HIV, 1996.
2. **Hardy WD** (Moderator), Chaisson R, Cohan R, Havlir D, Kotler D, Polsky B. Managing opportunistic infections: Panel discussion. Medscape HIV/AIDS 2(2), www.medscape.com/HIV, 1996.
3. Van der Horst C (Moderator), Anastos K, Follansbee S, **Hardy WD**, Markowitz M, Murphy R. HIV therapy: Panel discussion. Medscape HIV/AIDS 2(2), www.medscape.com/HIV, 1996.
4. Van der Horst C, Gallant J, **Hardy WD**, Kuritzkes D, Montaner J. Current controversies in antiretroviral management. 8th Clinical Options in HIV Symposium. Medscape HIV/AIDS 4(2), www.medscape.com/HIV, 1998.
5. **Hardy WD**. Drug design and discovery – tomorrow’s solutions for today’s problems. HIV DART 2000 – Frontiers in Drug Development for Antiretroviral Therapies, December 17, 2000. Medscape HIV/AIDS, www.medscape.com/HIV, 2000.
6. **Hardy WD**. Opportunistic infections and tumors in the HAART era. 5th International Congress on Drug Therapy in HIV Infection. October 22, 2000. Medscape HIV/AIDS, www.medscape.com/HIV, 2000.
7. **Hardy WD**. Advances in first-line antiretroviral therapy: They’re no longer all the same. XIII International AIDS Conference, July 14, 2000. Medscape HIV/AIDS, www.medscape.com/HIV, 2000.
8. **Hardy WD**. Positive results seen from treatment of primary HIV infection. 8th Conference on Retroviruses and Opportunistic Infections, February 4, 2001. Medscape HIV/AIDS, www.medscape.com/HIV, 2001.
9. **Hardy WD**. Promising early steps with gene therapy for HIV. 8th Conference on Retroviruses and Opportunistic Infections, February 4, 2001. Medscape HIV/AIDS, www.medscape.com/HIV, 2001.
10. Eron Jr JJ, **Hardy WD**, Powderly WG: Investigational antiretrovirals. Source: 2003 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 12, 2003.
11. Chaisson RE, **Hardy WD**, Polsky B: Opportunistic Infections and Coinfections. Source: 2003 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 17, 2003.

12. **Hardy WD**. New strategies: Optimizing antiretroviral therapy for treatment-experienced patients. Source: New Agents & Treatment Strategies for Treatment-Experienced HIV Patients. www.clinicaloptions.com, September 14, 2003.
13. Eron Jr JJ, Gallant JE, **Hardy WD**: Initial Therapy, Treatment Interruption, and Induction/Maintenance. 2004 International AIDS Conference. www.clinicaloptions.com, August 19, 2004.
14. Gallant JE, **Hardy WD**, Smith KY: Management of treatment-naïve patients. 2004 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 18, 2004.
15. Eron Jr JJ, Gulick RM, **Hardy WD**: Investigational antiretroviral agents. 2005 Conference on Retroviruses & Opportunistic Infections. www.clinicaloptions.com, April 12, 2005.
16. Gallant JE, **Hardy WD**, Smith KY. Persistence of Transmitted Resistance. 2004 Conference on Retroviruses and Opportunistic Infections, www.clinicaloptions.com, June 2005.
17. **Hardy WD**: Current Treatment Options. Source: New Agents & Treatment for Treatment-Experienced HIV Patients, www.clinicaloptions.com, June 8, 2005.
18. Eron Jr JJ, Gallant JE, **Hardy WD**: Long-term follow-up of GS 903: Tenofovir vs Stavudine. Source: 2004 International AIDS Conference. www.clinicaloptions.com, June 23, 2005.
19. Eron Jr JJ, **Hardy WD**, Powderly: Tipranavir. Source: 2003 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, June 23, 2005.
20. Eron Jr JJ, Gulick RM, **Hardy WD**: Novel Reverse Transcriptase Inhibitors. 2005 Conference on Retroviruses and Opportunistic Infections, www.clinicaloptions.com, July 2005.
21. Gallant JE, **Hardy WD**, Schechter M: When to start ART? Source: 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment. www.clinicaloptions.com, October 2005.
22. Gallant JE, **Hardy WD**, Schechter M: First-line therapy and switch strategies. 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment. www.clinicaloptions.com, October 17, 2005.
23. Gallant JE, **Hardy WD**, Sanne IM: MK-0518: An investigational integrase inhibitor in treatment-naïve patients. Source: 2005 European AIDS Conference. www.clinicaloptions.com, January 2006.
24. **Hardy WD**: Blocking the Gate: Entry inhibitor proof of concept. www.clinicaloptions.com, Journal Options, Jan 6, 2006.

25. Gallant JE, **Hardy WD**, Sanne IM: Clinical studies of antiretroviral therapy. Source: 2005 European AIDS Conference. www.clinicaloptions.com, January 18, 2006.
26. **Hardy WD**: The final nail? What the CD4+ T-cell count-guided treatment interruption strategy has taught us. News and Comment. www.clinicaloptions.com, February 8, 2006.
27. **Hardy WD**. Case Challenge: Management of a multiclass-experienced HIV-infected patient with virologic failure. Source: New Agents and Treatment Strategies for Treatment-Experienced HIV Patients. www.clinicaloptions.com, March 2006.
28. Gallant JE, Chaisson RE, Eron Eron Jr JJ, Fletcher CV, **Hardy WD**, Polsky B, Schechter M, Smith KY, Squires KE, Zolopa AR: Update from 2006 CROI: First-line therapy, pharmacology, metabolics. CCO Expert Recap of Data From the 2006 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 31, 2006.
29. Gallant JE, **Hardy WD**, Smith KY: ACTG 5170: Successful Treatments interruption in patients with high nadir CD4+ cell counts. Source: 2006 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 20, 2006.
30. Gallant JE, Smith KY, **Hardy WD**: First-line therapy and switch strategies. Source: 2006 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, March 23, 2006.
31. Eron Jr JJ, Chaisson RE, Fletcher CV, Gallant JE, **Hardy WD**, Hodder S, Polsky B, Schechter M, Smith KY, Squires KE, Zolopa AR: Expert Recap - Update From 2006 CROI: Resistance, Investigational Antiretrovirals, Hepatitis and Opportunistic Coinfections, Resource-Poor Settings. www.clinicaloptions.com, April 5, 2006.
32. Gallant JE, Chaisson RE, Currier JS, Eron Jr JJ, **Hardy WD**, Hodder S, Kotler DP, Polsky B, Powderly WG, Smith KY, Squires KE, Horst CVD, Zolopa AR: Update from the 2006 International AIDS Conference. CCO Expert Recap of Data from the 2006 International AIDS Conference. www.clinicaloptions.com, October 12, 2006.
33. **Hardy WD**, Squires KE, Zolopa AR: Postpartum impact of resistance mutations selected during antiretroviral treatment of pregnant HIV-infected women. 2007 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, April 12, 2007.
34. **Hardy WD**, Squires KE, Zolopa AR: Resistance and management of treatment-experienced patients. Source: 2007 Conference on Retroviruses and Opportunistic Infections. www.clinicaloptions.com, April 18, 2007.
35. **Hardy WD**. Resistance and management of treatment-experienced patients. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, www.clinicaloptions.com, Sydney Australia, July 22-25, 2007.

36. **Hardy WD**, Hicks CB, Powderly WG: Resistance and management of treatment-experienced patients. Source: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. www.clinicaloptions.com, September 2007.
37. **Hardy WD**: Case Challenge: Management of a patient with virologic failure of an initial PI-based regimen. Source: From Theory to Practice: Strategies for the Successful Management of Treatment-experienced Patients. www.clinicaloptions.com, September 14, 2007.
38. **Hardy WD**, Hicks CB, Powderly: Influence of baseline resistance on antiretroviral response rates. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. www.clinicaloptions.com, September 18, 2007.
39. Eron Jr JJ, **Hardy WD**, Hicks CB: Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents. www.clinicaloptions.com, December 17, 2007.
40. **Hardy WD**: Expert Viewpoint: How Many Agents Does a Treatment-Experienced Patient Need? Clinical Care Options HIV CME/CE-certified Program: In-Page Video/Audio Bimonthly Series, Vol 1, Edition 2; www.clinicaloptions.com, June 2008.
41. **Hardy WD**: Managing Treatment-Experienced Patients with HIV Strains Resistant to Two or More Agents, Peer View Update: Targeting a Unique Enzyme, Peer View Update Publishing, www.pvupdate.com, 2008.

Abstracts

1. Wolfe P, Gottlieb MS, Fahey JL, Knight S, **Hardy WD**, Eppolito L. Prognosis indicators in persistent generalized lymphadenopathy. In: The 1st International Conference on Acquired Immunodeficiency Syndrome: Abstracts. American College of Chest Physicians, Philadelphia, 1985.
2. **Hardy WD**, Wolfe PR, Gottlieb MS, Knight S, Mitsuyasu RT, Weisman J, Young LS. Fansidar prophylaxis for *Pneumocystis carinii* pneumonia. In: The 1st International Conference on Acquired Immunodeficiency Syndrome: Abstracts. American College of Chest Physicians, Philadelphia, 1985.
3. Holland GN, Sidikaro Y, Kreiger AK, Sakamoto M, **Hardy WD**, Gottlieb MS, Bryson YJ, Cherry JD. Treatment for CMV retinopathy in patients with AIDS: 9- (2-hydroxyl-1-(hydroxymethyl) ethoxymethyl) guanine. In: Official Program of the Annual Meeting of the American Academy of Ophthalmology, New Orleans, 1986.
4. Wolfe PR, Gottlieb MS, **Hardy WD**, Chafey S. Suramin in AIDS and ARC: Results of a pilot toxicity/efficacy study. In: Official Program of the 2nd International Conference on Acquired Immunodeficiency Syndrome (AIDS). Paris, 1986.

5. **Hardy WD**, Frenkel LM, Gottlieb MS, Bryson YJ. Varicella zoster virus infection (VZV): An early indicator of HTLV-III-induced immunosuppression. In: Official Program of the 2nd International Conference on Acquired Immunodeficiency Syndrome (AIDS). Paris, 1986.
6. Holland GN, **Hardy WD**, Sidikaro Y, Cedarberg DM, Cherry JD, Gottlieb MS. Treatment for CMV retinopathy in patients with AIDS: 9-(2-hydroxyl-1- (hydroxymethyl) ethoxymethyl) guanine In: Official Program of the 2nd International Conference on Acquired Immunodeficiency Syndrome (AIDS). Paris, 1986.
7. **Hardy WD**, Wolfe PR, Gottlieb MS, Knight S, Mitsuyasu RT, Young LS. Long- term follow-up fansidar prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with AIDS. In: Official Program of the Third International Conference on Acquired Immunodeficiency Syndrome. Washington, DC, 1987.
8. **Hardy WD**, Engstrom R, Holland G, Meiselman J. Abnormal blood rheologic factors in patients with HIV-associated conjunctival and retinal microvasculopathy. In. Official Program of the Fourth International Conference on AIDS. Stockholm, 1:7106, 1988.
9. Janoff EN, **Hardy WD**, Smith PD, Chafey S, Fall H, et al. Humoral immunity responses to recall antigens are intact in persons with HIV infection. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, p:810, 1989.
10. Wu AW, Rubin HR, Mathews WC, Brysk LM, **Hardy WD**, et al. A brief health status instrument for use in AIDS clinical trials. In: Official Program of the Fifth International Conference on AIDS. Montreal, WBP254, 1989.
11. **Hardy WD**, Holzman RS, Avramis V, Fall H, et al. Clinical and pharmacokinetic interactions of combined zidovudine therapy and sulfadoxine-pyrimethamine (Fansidar) prophylaxis in post-PCP AIDS patients. In: Official Program of the Fifth International Conference on AIDS. Montreal, MBP123, 1989.
12. Tan C, **Hardy WD**, Chafey S, Karol C. Foscarnet induction and maintenance therapy for acyclovir-resistant herpes simplex infections in AIDS. In: Official Program of the Sixth International Conference on AIDS. San Francisco, ThB447, 1990.
13. Waskin H, **Hardy WD**, McClain N, Fall H. Diabetes mellitus in HIV positive patients post-pneumocystis pneumonia and the impact of aerosolized pentamidine. In: Official Program of the Sixth International Conference on AIDS. San Francisco, ThB422, 1990.
14. Wool M, Magpantay L, **Hardy WD**, Chen I. Systemic lupus erythematosus mimicking HIV infection. In: Official Program of the Sixth International Conference on AIDS. San Francisco, 2039, 1990.

15. **Hardy WD**, Spector S, Polsky B, Heath-Chiozzi M, Holland G, Freeman W, Heinemann MH, Sharuk G, Feinberg J, Power M. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) vs ganciclovir alone for cytomegalovirus retinitis in AIDS (ACTG 073) In: Official Program of the Sixth International Conference on AIDS. San Francisco, 1:FB92, 1990.
16. Jacobson MA, Causey D, Polsky B, **Hardy WD**, Feinberg JE, et al. Dose- comparative study of daily intravenous maintenance foscarnet therapy for cytomegalovirus retinitis in AIDS patients (ACTG 015/915). In: Official Program of the Sixth International Conference on AIDS. San Francisco, FB92, 1990.
17. **Hardy WD**, Spector S, Polsky B, Crumpacker C, Holland G, Freeman W, Heinemann MH, Sharuk G, Feinberg J. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) vs ganciclovir alone for cytomegalovirus retinitis in AIDS (ACTG 073): preliminary data In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
18. **Hardy WD**, Chafey S, Tan C, Bryson Y, Mroz J, Martin-Manley S. Randomized trial of foscarnet induction and maintenance therapy for acyclovir-resistant herpes simplex infections in AIDS. In: Official Program of the Seventh International Conference on AIDS. Florence, WB2305, 1991.
19. Wool M, **Hardy WD**, Holland G, Chafey S, Bonnem E. Phase III recombinant GM-CSF and ganciclovir in neutropenic AIDS patients with CMV retinitis. In: Official Program of the Seventh International Conference on AIDS. Florence, WB2273, 1991.
20. Waskin H, **Hardy WD**, McClain N, Rayle K, Johiro A, Kreuger S. Diabetes mellitus and pentamidine therapy. In: Official Program of the Seventh International Conference on AIDS. Florence, WB2253, 1991.
21. **Hardy WD**, Holzman R, Feinberg J, Finklestein D, et al. Trimethoprim-sulfamethoxazole vs aerosolized pentamidine for secondary prophylaxis of *Pneumocystis carinii* pneumonia in AIDS patients: A prospective, randomized, controlled clinical trial (ACTG 021). In: Official Program of the Third European Conference on Clinical Aspects and Treatment of HIV Infection. Paris, France, Abstract 016, 1992.
22. **Hardy WD**, Spector S, Polsky B, Crumpacker C, van der Horst C, et al. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) vs ganciclovir alone for cytomegalovirus retinitis in AIDS (ACTG 073). In: Official Program of the Eight International Conference on AIDS. Amsterdam, MoA0005, 1992.
23. Petersen E, Ramirez-Ronda C, Schwartz R, Peterson D, **Hardy WD**, Sacks H, Follansbee S, et al. Findings from a phase II study of stavudine (d4T). In: Official Program of the Eight International Conference on AIDS. Amsterdam, PoB3023, 1992.

24. **Hardy WD**, Bozzette S, Safrin S, Black J, Farthing C, Saag M and the ACTG 081, 108, 156 and MSG 25 Teams. Results from recent therapeutic and prophylactic clinical trials for opportunistic infections (OIs) from the United States. Presented at the 2nd International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 9-12, 1992.
25. **Hardy WD**, Holzman R, Feinberg J, Finklestein D, et al. Trimethoprim- sulfamethoxazole vs aerosolized pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia in AIDS patients: A prospective, randomized, controlled clinical trial (ACTG 021). *AIDS* 1992; 6(S1):S18. Presented at the 2nd International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 9-12, 1992.
26. **Hardy WD**; Liu C; Xie Y, Folks T, Chen ISY. Foamy Viruses (FVs) as potential vectors for HIV vaccine and gene therapy applications". Presented at the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, San Francisco, CA. [Abstract B-25], 2004.
27. **Hardy WD**; Liu C; Xie Y; Folks T; Chen IYS. Foamy virus vectors as potential vaccines against HIV: rationale and preliminary experimental data. Presented at the 5th World Foamy Virus Conference, Wuerzburg, Germany, July 9-11. [Abstract # 32], 2004.
28. **Hardy WD**; Liu C; Xie Y; Folks T; Chen IYS. Foamy viruses (FVs): potential vectors for HIV vaccine. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts [Abstract # 262]. February 22-25, 2005.
29. **Hardy WD**, Liu C, Yiming X, Folks T, Chen I. Foamy virus vectors for potential gene therapy and HIV vaccine applications. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil,. [Abstract # TuPe13.4B05], July 24-27, 2005.
30. **Hardy WD**; Liu C; Xie Y; Folks T; Chen IYS. Foamy Virus (FV) Vectors Persistently Express High Levels of HIV-1 gag: Potential for HIV Vaccines. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, [Abstract # 472], February 5-8, 2006.
31. **Hardy WD**; Liu C; Xie Y; Folks T; Chen IYS. Recombinant HIV-1 gag /Foamy Virus Vectors: Evidence for Persistent p24 Antigen Expression in Human MDDCs. Oral presentation at the 6th World Foamy Virus Conference, Seattle, Washington, [Abstract # 28], August 3-5, 2006.
32. **Hardy WD**; Liu C; Xie Y; Folks T; Chen IYS. Recombinant HIV-1 gag /Foamy Virus Vectors Express p24 Antigen for 6 Months and Process HIV-1gag Similar to Native Virus. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California [Abstract # C-181], February 25-28, 2007.
33. **Hardy WD**; Berger D, De Paepe E, Meyer S, Moriarty D, Spinosa-Guzman S, Mrus J. Influence of Baseline (BL) Factors on Virologic Response to Darunavir/Ritonavir (DRV/r)

- vs Lopinavir/R (LPV/r): Week 48 Outcome in TITAN. Oral presentation at the 45th Infectious Disease Society of America (IDSA) Annual Conference, San Diego, CA, October 5-7, [Abstract 1524], 2007.
34. **Hardy WD**, Liu C, Folks T, Chen I. Recombinant Foamy Virus (rFV) Vectors Persistently Express HIV-1 gag Proteins: Potential for HIV Vaccine. Poster presentation at 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-6, [Abstract 499], 2008.
 35. **Hardy WD**, Reynes J, Konourina I, Wheeler D, Moreno S, Van Der Ryst E, Towner W, Horban A, Mayer, Goodrich J. Efficacy and Safety of Maraviroc Plus Optimized Background Therapy in Treatment-experienced Patients Infected with CCR-5-tropic HIV-1: 48-Weeks Combined Analysis of the Motivate Studies. Poster presentation at 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-6 [Abstract 792], 2008.
 36. **Hardy WD**, Gulick R, Mayer H, Fatkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J. Efficacy and Safety of Maraviroc in Treatment-experienced Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 and 2 Studies. Abstract presentation at the 9th International Congress on Drug Therapy in HIV Infection, Glasgow, UK [Abstract #425], November 9-13, 2008.
 37. Vrouenraets SME, Fernandez Garcia E, Jackson A, Raffi R, Jayaweera DT, Katlama C, Fisher M, Slama L, **Hardy WD**, Mauss S, DeJesus E, van Eeden A, Prelutsky D, Wit FWNM, Moyle G and Reiss P for the BASIC Study Group. Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofovir/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial. Poster presentation at 11th International Workshop on Adverse Drug Reactions and Comorbidities in HIV (IWADR) 26-28 October 2009, Philadelphia.
 38. Hardy DJ, Goodkin K., Lopez E., Morales G., Buitron M., Charles D., & **Hardy, WD**. The role of working memory in neuropsychological test performance in older HIV-seropositive adults. Poster presentation at The British Psychological Society Annual Conference, Stratford-upon-Avon, United Kingdom, April 14-16, 2010.
 39. E Blumberg B Barin, R Bloom, M Roland, L Frassetto, B Murphy, M Pavlakis, D Roth, J Moore, C Davis, S Saltzberg, D Fine, M Josephson, G M Lyon, R Zhang, V Stosor, K Brayman, L Johnson, R Shapiro, B Weikert, R Fatica, G Mogilishetty, **D Hardy** and P Stock. BK Virus Infection Is Not A Significant Cause of Graft Loss in HIV+ Kidney Recipients. Oral presentation [abstract #798] at 2011 American Transplant Congress, Philadelphia, PA, April 30 – May 4, 2011.
 40. Richmond G, Robbins W, Bredeek F, Shalit P, **Hardy D**, Workowski K, Block M, Towner W, Lutz T, Orkin C, Szwarcberg J, Quirk E, Liu H, Wei X, Rhee M, Piontkowsky D. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and

Favorable tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Patients >50 Years. Poster presentation [abstract #H-879] at 2012 the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 9-12, 2012.